Les societes biotechnologiques de France et leur annee de creation.

COMPANY	YEAR	LOCATION	BUSINESS MODEL	MANAGEMENT	FOCUS	STAGE
Abcys	1999	IDF	Design, Reagents	Start-up |	Cell	Trade
		Paris	Key words: Immunology, Cytokines, Cell culture, Stem cells, Production, Distribution, Third Parties, Gemstem	Managing Dir.-CEO: Martin (Thierry) [born 1961]
			Mission: to design, manufacture and distribute biotechnology reagents, and to develop own research on Stem Cells	Sc.Dir.-CSO:
			Clients: Research institutes, Hospitals, Universities, Pharmaceutical industry, Diagnostic industry	Fin.Dir.-CFO:
www.abcysonline.com			Age: 21 year(s)	BusDev:
				Financers (Hist.): undisclosed
				Communication : no website corporate information or press release since 2006
AB Science	2001	IDF	Discovery, Drugs	Start-up |	Cancers	Clinical
		Paris	Key words: Mastocytosis, Inhibitors, Tyrosine Kinase, Anticancer, Inflammation, Auto-immune diseases	Managing Dir.-CEO: Moussy (Alain) [founder, born 1965, MBA Wharton, ENSTA, ex-Carrefour (Dir M&A)]
			Mission: to develop innovative tyrosine kinase inhibitors for auto-immune diseases in man and animals	Sc.Dir.-CSO:
			Clients: Prescribers, Veterinarians	Fin.Dir.-CFO: Guy (Laurent)
www.ab-science.com			Age: 19 year(s)	BusDev:
				Financers (Hist.): privately owned (registered capital 2007 = 0.29 M€)
				note (September 2011) : sales are derived from masitinib in veterinary practice
Adocia	2005	Rhône-Alpes	Discovery, Drugs	Personal venture |	Multiple	Clinical
		Lyon	Key words: Growth factors, Natural proteins, Regenerating organs, Osteoporosis, Diabetes, Aging population, BioChaperone	Managing Dir.-CEO: Soula (Gérard) [born 1945, ex-Rhône Poulenc, Flamel Technologies (founder)]
			Mission: to develop innovative drugs for regenerating organs affected by diseases related to the aging of the population, such as osteoporosis and diabetes	Sc.Dir.-CSO: Soula (Olivier) [born 1970, PhD polymer science, MBA-IAE (Lyon), ex-Flamel Technologies]
			Clients: Pharmaceutical industry	Fin.Dir.-CFO: Danaguezian (Valérie)
www.no-website.net			Age: 15 year(s)	BusDev: Soula (Rémi)
				Financers (Hist.): AGF P.E., Bioam Gestion, Société Générale A.M., Viveris Management, Business angels (Alain Tornier and Jean Deléage [died in 2011]), InnoBio, SHAM (Société Hospitalière d’Assurances Mutuelles)
Advicenne Pharma	2007	Méditerranée	Discovery, Drugs	Personal venture |	CNS	Preclin
		Castries	Key words: CNS, Pediatry, Emergent diseases	Managing Dir.-CEO: Granier (Luc-André) [founder, born 1954, Ph.D., M.D., ex-Forenap, Eli Lilly, Syntem]
		(near Nîmes)	Mission: development and marketing of drugs for pediatric use mainly for the treatment of Central Nervous System Diseases (including autism, feeding behaviours dysfunctions and neurodegenerative disorders)	Oper.Dir.-COO: Roussel-Maupetit (Caroline) [born 1969, Eng., ex-Syntem (co-founder), Protéine Performance]
			Clients: undisclosed	Sc.Dir.-CSO:
www.advicenne.com			Age: 13 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): privately owned (registered capital 2007 = 0.13 M€), but CDC Entreprises with a board member
				Communication : website under development (March, September 2011, October 2012)
Affichem	2002	Midi-Pyrénées	Design, Drugs	Start-up | Managing Dir.-CEO: Silvente (Stéphane) [co-founder, born 1968, MBA, Ms. International Business, also chairman]	Cancers	Preclin
		Toulouse	(also Design, Diagnostics)	Sc.Dir.-CSO: Poirot (Marc) [co-founder, born 1960, also Inserm, Ph.D. chemical biology]
			Key words: Proteins, Dendrogenins, Cancer, Degenerative diseases	Pharm.Dir.: Silvente-Poirot (Sandrine) [co-founder, also Inserm, Ph.D. molecular pharmacology]
			Mission: to develop drug candidates based on proprietary new family of compounds derived from sterols, Dendrogenines A and B, in cancer and neurodegenerative diseases	Fin.Dir.-CFO:
www.affichem.com			Clients: Prescribers	BusDev:
			Age: 18 year(s)	Financers (Hist.): privately owned, undisclosed (opening of capital proposed to individuals in 2012, up to 8.6%)
Agate Bioservices	2005	Méditerranée	Contract, Services	Personal venture |	Target	Preclin
		Alès	(also, Discovery, Targets)	Managing Dir.-CEO: Chaabihi (Hassan) [founder, born 1962, Ph.D. molecular biology, ex-Protéines Performance, Quantum Biotechnologies]
		(near Nîmes)	Key words: Gene expression, Protein production, Gene delivery, Insect cells expression, Baculovirus, BacTen	Sc.Dir.-CSO: Chaabihi (Hassan)
			Mission: to provide third parties with services ranging from gene cloning to protein (or virus) production (resp. purification), acting as a vector developer, either for protein production or for gene transfer, as well as a manufacturing partner, to to develop new systems and technologies in the gene expression, gene transfer and delivery areas	Fin.Dir.-CFO:
www.agatebioservices.com			Clients: Pharmaceutical industry, Biotech, Research labs	BusDev:
			Age: 15 year(s)	Financers (Hist.): privately owned (registered capital 2006 = 0.008 M€)
				Communication : no website news update since November 2006
Aisa Therapeutics	2005	IDF	Discovery, Drugs	Personal venture |	Inflammation	Preclin
		Évry	Key words: Vascular endothelium, Inflammation, Nanomolarity, Colitis, Cystic cancer, Nutraceuticals, Anti-stress	Managing Dir.-CEO: d’Alessio (Patrizia) [founder, born 1952, M.D., Ph.D., ex-Inserm]
		(near Paris)	Mission: to develop new anti-inflammatory molecules for rhumatoid arthritis, obesity, degenerative diseases, aging and metastatic spreading, based on the modulation-inhibition process in vascular permeability	Sc.Dir.-CSO:
			Clients: pharmaceutical industry, veterinary industry	Fin.Dir.-CFO:
www.aisa-tx.com			Age: 15 year(s)	BusDev: Loumeau (Jean-François) [M.D., MBA]
				Financers (Hist.): Critt Chimie, Anvar
Alfact Innovation	2006	IDF	Discovery, Drugs	Personal venture |	Cancers	Preclin
		Paris	Key words: Liver Failure, Liver Cancer	Managing Dir.-CEO: Amouyal (Gilles) [born 1957, M.D., Ph.D.]
			Mission: to develop biopharmaceuticals for liver diseases	Sc.Dir.-CSO: Bréchot (Christian) [M.D., Ph.D., V.P. Biomérieux, ex-Inserm]
			Clients: undisclosed	Oper.Dir.-COO: Mariau (Jérémie) [M.Sc. human genetic, Eng. Supagro]
alfactinnovation.com			Age: 15 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): unknown (registered capital 2008 = 1.48 M€)
Alizé Pharma	2007	Rhône-Alpes	Discovery, Drugs	Start-up |	Multiple	Preclin
		Ecully	Key words: Diabetes, Leukaemia, Recombinant L-asparaginase	Managing Dir.-CEO: Abribat (Thierry) [co-founder, born 1964, Ph.D., Vet.D., ex-Sanofi-Recherche, Theratechnologies, OPi (CEO)]
		(near Lyon)	Mission: to develop innovative therapeutics for the treatment of metabolic diseases and cancers (after early acquisition of products from Biotechs and in-house preliminary development)	Sc.Dir.-CSO:
			Clients: Pharmaceutical industry	Fin.Dir.-CFO:
www.alz-pharma.com			Age: 13 year(s)	BusDev: Delale (Thomas)
				Financers (Hist.): Octalfa (Gilles Alberici, board member), CEMA (Canada, André de Villers, board member), SHAM (registered capital 2007 = 0.052 M€)
Ambiotis	2007	Midi-Pyrénées	Contract, Services (also, Research, Drugs)	Personal venture |	Inflammation	Subcontractor
		Toulouse	Key words: Validation, Anti-inflammatory, Immunostimulatory, Biomarkers	Managing Dir.-CEO: Dubourdeau (Marc) [founder, born 1973, M.D., Ph.D. immunology, Ms. Management (Toulouse)]
			Mission: to provide preclinical testing services (cellular and animal experiments) for anti-inflammatory and immunostimulatory assays of third parties, and to undertake own research specialized in the study of lipoxins, resolvins and protectins	Sc.Dir.-CSO: Dubourdeau (Marc)
			Clients: Pharmaceutical industry, Cosmetics, Nutraceutics, Agro-food	Fin.Dir.-CFO:
www.ambiotis.com			Age: 13 year(s)	BusDev:
				Financers (Hist.): privately owned (registered capital 2007 = 0.04 M€)
Anaconda Pharma	2003	IDF	Discovery, Drugs	Spin-off |	Cancers	Preclin
		Paris	Key words: Protein interactions, Condyloma, Anti-viral	Managing Dir.-CEO: Blumenfeld (Marta) [born 1955, Ph.D. Biochemistry, ex-Genset]
			Mission: to develop a proprietary platform for the discovery of small molecules that disrupt protein:protein interactions, as a distinct unexploited class of pharmaceutical targets, due to the difficulty of recognizing drugable hot-spots on the surface of interacting proteins	Sc.Dir.-CSO:
			Clients: Prescribers	Med.Dir.: Compère (Delphine) [Ph.D. organic chemistry, ex-Pfizer, Cerep]
www.anacondapharma.com			Age: 17 year(s)	Fin.Dir.-CFO: Bali (Ismahane) [Ms accounting, ex-Audit and Diagnostic]
				BusDev:
				Financers (Hist.): privately owned (private investors)
Aptys Pharmaceuticals	2002	Centre	Contract, Research	Spin-off |	Multiple	Preclin
		Clermont-Ferrand	(also, Delivery, Drugs)	Managing Dir.-CEO: Boutignon (François) [co-founder, born 1960, Ph.D. protein biochemistry, ex-Europeptides]
			Key words: Formulation, Peptides, ADHAPT, Bi-Gel, Generic Plus, Insulin delivery	Sc.Dir.-CSO: Boutignon (François)
			Mission: to develop formulation of new chemical entities and peptides/proteins, reformulation of registered molecules and novel drug delivery systems for third parties, to develop internal research programs for own technological portfolio, based on subcontractor cash flow	Techn.Dir.-CTO: Barres (Thomas) [Ms.Sc., Pharm. D., ex-LPH Industries]
www.aptys-pharmaceuticals.com			Clients: Pharmaceutical industry, Biotechs	Fin.Dir.-CFO:
			Age: 18 year(s)	BusDev:
				Financers (Hist.): Sofimac Partners, Crédit Agricole Centre France, privately owned (registered capital 2007 = 0.10 M€)
Ariana Pharmaceuticals	2003	IDF	Contract, Knowledge	Spin-off |	Data	Subcontractor
		Paris	Key words: Discovery acceleration, Virtual screening, Knowledge management, Decision support, KEM, eADMET, Bioassays	Managing Dir.-CEO: Afshar (Mohammad) [co-founder, born 1966, Ph.D. biochemistry, ex-RiboTargets]
			Mission: to provide decision-support tools, in order to accelerate drug discovery of third parties	Sc.Dir.-CSO:
			Clients: Pharmaceutical industry, Biotechs	Tech.Dir.-CTO: Kuras (Mariana) [Ph.D. biophysics, ex-Biosystems, Pfizer]
www.arianapharma.com			Age: 17 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): privately owned, Institut Pasteur, Vizille Capital Innovation
Aterovax	2006	IDF	Discovery, Development, Diagnostics and Immunology-vaccines	Start-up |	Cardiovasc	1st product soon available
		Paris	Key words: Tests, Atherosclerosis, sPLA2 Activity Test, Atherosclerosis Risk Assessment, Biomarker for Cardiovascular Risk Evaluation and Prevention, Secreted Phospholipase A2 Activity, In Vitro Diagnostic Assay, Immunotherapy	Managing Dir.-CEO: Surun (Dominique) [M.D., MBA (CPA), ex-Meda Pharma, Janssen Cilag, 3M]
			Mission: to develop innovative solutions to predict, diagnose, prevent and treat cardiovascular diseases through a proprietary understanding of atherosclerosis	Sc.Dir.-CSO: Valentin (Emmanuel) [Ph.D.]
			Clients: undisclosed	Fin.Dir.-CFO:
www.aterovax.com			Age: 14 year(s)	Regul.Dir.: Doceur (Paula) [Ph.D.]
				BusDev:
				Financers (Hist.): SGAM (registered capital 2008 = 0.123 M€)
				Communication : website under re-construction (October 2012), legal undetailed changes at the end of 2011 – beginning 2012 (new chairman of the board, capital increase)
Atlantic Bone Screen	2005	Bretagne	Contract, Services	Personal venture |	Inflammation	Subcontractor
		Nantes	Key words: Validation, In-vivo testing, Osteo-articular pathologies, LPRO	Managing Dir.-CEO: Le Bot (Ronan) [co-founder, born 1977, Pharm.D.]
			Mission: to offer in vitro and in vivo (patented animal models) services dedicated to validation of proof of concept in osteoarticular pathologies, and (Atlanchim) to act as a subcontractor for the synthesis of new molecules	Sc.Dir.-CSO:
			Clients: Pharmaceutical industry, Biotechs, Chemical industry, Food industry	Fin.Dir.-CFO:
www.atlantic-bone-screen.com			Age: 15 year(s)	BusDev: Porcher (Elisabeth) [MBA, ex-Eurocopter]
				Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€), internal growth (no outside investors searched)
Aureus Sciences	2000	IDF	Contract, Knowledge	Start-up |	Data	Subcontractor
		Paris	Key words: Bioinformatics, Knowledge management, Molecular modeling, Data structuring, AurSCOPE, AurPROFILE	Managing Dir.-CEO: Theodosiou (Jason) [born 1959, Ph.D. organic chemistry, MBA Sup de Co Paris, ex-MDL Information Systems, EMAX/SciQuest, LION Bioscience, Elsevier
			Mission: to provide knowledge management solutions to accelerate life science discovery for third parties	Sc.Dir.-CSO:
			Clients: Pharmaceutical industry, Biotechs	Dev.Dir.: Barberan (Olivier) [Ph.D.]
www.aureus-sciences.com			Age: 21 year(s)	Fin.Dir.-CFO:
				MktgComm:
				BusDev:
				Financers (Hist.): Bioam, AXA, FCJE (CDC), Matignon, OTC-AM
				Note : the news thread astutely mixes own events and general R&D major findings external to the company
B Cell Design	2008	Centre	Discover, Drugs	Personal venture |	Cancers	Proof-of-Concept
		Limoges	Key words: Humanised antibodies	Managing Dir.-CEO: Sainte-Laudy (Jean) [born 1946, Ph.D. immunology, ex-Pasteur Cerba]
			Mission: to develop, manufacture humanised IgA and IgG antibodies from genetically modified mice	Sc.Dir.-CSO: Cuvillier (Armelle) [Ph.D. health biology]
			Clients: Clinical labs, Research labs, Medical imaging, Therapists	Techn.Dir.-CTO: Champier (Gaël) [M.S. biotechnologies]
www.b-cell-design.com			Age: 13 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): Limousin Participation, Limousin Expansion, Limousin Business Angels
BioAlliance Pharma	1997	IDF	Discovery, Drugs	Start-up |	Cancers	Launch
		Paris	(also Delivery, Drugs)	Managing Dir.-CEO: Greciet (Judith) [Pharm.D., ex-Eisai, Wyeth, LFB, Zeneca, Pharmacia]
			Key words: Cancer, HIV, Opportunistic infections	Oper.Dir.-COO:
			Mission: to discover, develop and market innovative treatments rapidly evolving therapeutic markets -cancer, serious viral diseases (such as HIV) and opportunistic infections- with NCE’s ans drug delivery improvements	Med.Dir.-CMO: Attali (Pierre) [M.D., M.Sc., ex-Synthelabo, Sanofi, OSMO (co-founder), Molecular Engines Laboratories, Urogene]
www.bioalliancepharma.com			Clients: Prescribers	Sc.Dir.-CSO: Kayitalire (Louis) [M.D., Institut Gustave Roussy, ex-Eli Lilly, B.M.S., Cephalon]
			Age: 23 year(s)	Fin.Dir.-CFO: Fellman (Nicolas) [MBA, ex-Pfizer, Ernst & Young]
				SalesMktg: Dupré (Florence)
				BusDev:
				Financers (Hist.): 3i, Auriga Partners, ING, Capricorn Venture, ABN-AMRO, SPEF Ventures, AGF P.E., Public
				Note : Financière de la Montagne (a company of family Besançon-Trébouta, previously holding Laboratoires Delagrange, part of Synthelabo, acquired by Sanofi) holds 10% of capital in December 2012
Biocortech	2001	IDF	Discovery, Drugs	Spin-off |	CNS	Preclin
		Paris	Key words: Neuro-psychiatric diseases, Biomarkers, Serotonin, Glutamate	Managing Dir.-CEO: Weissmann-Pujol (Dinah) [co-founder, born 1951, Pharm.D., Ph.D. neurobiology, ex-Roussel Uclaf, CNRS]
			Mission: to develop novel biomarkers and treatments for psychiatric disorders, including depression, bipolar disorders, schizophrenia, and cognitive deficits	Sc.Dir.-CSO: Pujol (Jean-François) [co-founder, M.D., Ph.D., Hospital Professor, ex-Roussel Uclaf, INSERM and CNRS]
			Clients: Pharmaceutical industry (own development, up to clinical trials)	Fin.Dir.-CFO:
www.biocortech.com			Age: 19 year(s)	BusDev: Allemand (Frédéric) [M.D. cardiology, ex-Hybrigenics, Bayer, Syngenta, Biovector Therapeutics, Hybrigenics, Genopole Entreprises, Medincell, Surfactis, Phenopro]
				Financers (Hist.): Institut Pasteur, business angels
BioCydex	2002	Aquitaine	Delivery, Drugs	Personal venture |	Ophthamo	Preclin
		Poitiers	(also, Contract, Services)	Managing Dir.-CEO: Belgsir (El Mustapha) [co-founder, born 1958, Ph.D., ex-CNRS]
			Key words: Ophthalmology, Cyclodextrins	Sc.Dir.-CSO: Cenatiempo (Yves) [co-founder, also board chairman till 2008, born 1950, Prof. biochemistry (Poitiers)]
			Mission: to develop new compound formulations in ophthalmology, cancerology, and organ preservation during transplantation	Fin.Dir.-CFO: Marembaud (Olivier) [born 1952, Engineer, ex-Frantour, Kelois, SNCF]
www.biocydex.com			Clients: Pharmaceutical industry (up to clinical stage)	BusDev:
			Age: 18 year(s)	Financers (Hist.): Oseo
Biométhodes	1997	IDF	Contract, Manufacturing	Personal venture |	Haemophilia	Trade
		Évry	(also Design, Drugs)	Managing Dir.-CEO: Amsallem (Gilles) [born 1954, ex-Mixis Genetics, Avesthagen (India), Dupont, Sorin Biomedica, Eurobio]
		(near Paris)	Key words: Protein engineering, Mutagenesis, Enzymes, Service Contracts, Haemophilia, High throughput screening, Manufacturing processes, THR selection scheme	Sc.Dir.-CSO: Winter (Bruno) [Ph.D., ex-AB Enzymes]
			Mission: to provide third parties with industrial processes based on proprietary know-how on improved enzymes, and to develop a next generation biologicals, with an initial focus on haemophilia, from sister company platform, Biométhodes Therapeutics	Techn.Dir.-CTO: Langvad (Niels) [ex-Biodiesel (co-founder)]
www.biomethodes.com			Clients: Pharmaceutical Industry, Biotechs, Chemical industry, Animal food	Fin.Dir.-CFO: Kazandjian (Raffy) [ex-CDC-Innovation Partners]
			Age: 23 year(s)	BusDev:
				Financers (Hist.): CDC Innovation, CIC Capital, FCJE (CDC)
Biom’up	2005	Rhône-Alpes	Development, Biomaterials & Medical devices	Spin-off |	Collagen	Trade
		Saint-Priest	(also, Contract, Manufacturing)	Managing Dir.-CEO: Picot (Sylvain) [co-founder, born 1978, Ph.D., Insa],
		(near Lyon)	Key words: Devices, Collagen, Glycosaminoglycans, Biopolymers, Grafting, Human reconstruction	Sc.Dir.-CSO: Forest (Patricia) [co-founder, born 1978, Ph.D., Insa], also COO]
			Mission: to develop and manufacture innovative biopolymers, such as collagens, for implantable Medical Devices, with a special focus on long term applications, and to design customized Purification Tools, particularly in affinity chromatography	Fin.Dir.-CFO:
www.biomup.com			Clients: Pharmaceutical industry, Cosmetic industry, Biotechs	SalesDir.: Francy (Philippe) [Sup de Co]
			Age: 15 year(s)	Financers (Hist.): privately owned, Créalys, SHAM, Sofimac Partners, Ameliane, Aquasourça, InnoBio, Viveris Management, OTC Asset Management
BioProtein Technologies	1998	IDF	Contract, Manufacturing	Personal venture |	Multiple	Preclin
		Jouy-en-Josas	Key words: Therapeutic proteins, Gene expression, Transgenic rabbits	Managing Dir.-CEO: Lignel (Jean)
		(near Paris)	Mission: to provide third parties with production of recombinant therapeutic proteins and vaccines in the milk of transgenic rabbits, as a fully integrated service from gene expression to industrial production of purified proteins and vaccines	Sc.Dir.-CSO: Ripoll (Pierre-Jean) [Ph.D., ex-Aventis, Biogemma]
			Clients: Pharma industry, Research labs, Biotechs	Fin.Dir.-CFO:
www.bioprotein.com			Age: 22 year(s)	BusDev: Fouassier (Alexandre) [Eng. INRA, M.Sc. biochemistry, also COO]
				Financers (Hist.): Société Générale A.M., Gilde, Creagro, Iwic, Anvar
BioQuanta	2003	IDF	Contract, Research	Personal venture |	Cancers	Patents
		Paris	(also, Discovery, Drugs)	Managing Dir.-CEO: Rabeuf (Rémi) [M.Sc. biology, MBA, ex-Roche (20 years)]
			Key words: Clinical biology, Biochemistry, Molecular modeling, In-silico Toxicity Prediction, In-vitro metabolic Exploration, Diagnostic kit and drug development	Sc.Dir.-CSO:
			Mission: to promote predictive and personalized medicine	Oper.Dir.-COO:
www.bioquanta.com			Clients: Biotech companies, Pharmaceutical, Food and Cosmetics industries	Fin.Dir.-CFO:
			Age: 17 year(s)	BusDev: Guidon (Romain) [MBA]
				Financers (Hist.): privately-owned (undisclosed private investors)
BioSystems International	2004	IDF	Design, Diagnostics	Spin-off |	Multiple	Trade
		Évry	Key words: Biomarkers, Drug discovery improvement, Development productivity, Serum proteins	Managing Dir.-CEO: Tirouflet (Jean-Pierre) [born 1950, ENA, ex-Rhodia (President), MEDEF, Rhône-Poulenc, Finance Ministry, Crédit National Bank
		(near Paris)	Mission: to discover and validate biomarkers through partnerships with pharmaceutical, biotechnology and diagnostics companies and in-house research programs or academic collaborations	Sc.Dir.-CSO: Takacs (Laszlo) [co-founder, born 1955, M.D., Ph.D., ex-Pfizer, Parke Davis, Amgen, NIH]
			Clients: Pharmaceutical industry (AstraZeneca), Biotechs	Tech.Dir.-CTO: Guttman (András) [co-founder, Ph.D. Chemistry, ex-Beckman Coulter]
www.biosys-intl.com			Age: 16 year(s)	Fin.Dir.-CFO: Hollai (Andrea) [MBA, ex-Hungarian Journalist’s Federation]
				BusDev:
				Financers (Hist.): Société Générale
				Note : a susidiary (research) in Hungary
BMSystems (Bio-Modeling)	2004	IDF	Discovery, Hub	Start-up |	Multiple	Proof-of-Concept
		Paris	Key words: Models, Proof of concept, Predictive efficacy, Validation, Spin-off	Managing Dir.-CEO: Géa (Manuel) [co-founder, born 1960, Eng. Centrale, ex-Hemispherx (CEO), Boehringer-Ingelheim, Colgate-Palmolive, McKinsey]
			Mission: to help clients run their life sciences R&D programs better, faster, cheaper and safer by applying CADI methodologies and tools, an operational systems biology approach (mainly in the fields of infectious diseases, neurology, psychiatry, oncology, dermatology and innovative bioprocesses)	Sc.Dir.-CSO: Iris (François) [also board chairman, born 1950, Ph.D., ex-Valigen (co-founder), Millenium]
			Clients: R&D departments (on a partnering basis), Financers (in case of spin-off)	Med.Dir.-CMO: Dine (Gérard) [M.D., Ph.D.]
www.bmsystems.net			Age: 16 year(s)	I.T.Dir.-CIO: Santamaria (Pablo) [Eng. Centrale, ex-Formitel, Glaxo]
				Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): privately-owned (no search for external investors)
Carmat	2008	IDF	Development, Device	Spin-off |	Cardiovasc	Preclin
		Vélizy	Key words: Artificial heart, Computer simulation, Electronic captors, Bioprothesis	Managing Dir.-CEO: Conviti (Marcello) [born 1952, Ph.D., MBA, ex-Edwards Lifesciences, Sorin]
		(near Paris)	Mission: to clinically develop, then market a fully implantable artificial heart for patients suffering in the aftermath of a massive heart attack or with late-stage heart failure and for whom standard drug therapy, ventricular assistance and/or a heart transplant have failed or are not possible	Sc.Dir.-CSO: Carpentier (Alain) [born 1933, co-founder, M.D. (surgery), Hospital Professor]
			Clients: Hospitals	Fin.Dir.-CFO:
www.carmatsas.com			Age: 12 year(s)	MktgComm: Leroy (Valérie) [Ms. Mktg (Paris), ex-Toshiba Systèmes, Medtronic, Edwards Lifesciences]
				BusDev:
				Financers (Hist.): Truffle Capital, Oseo, EADS
				Note : company first sourced as a J.V. Carpentier-Matra, in 1993 (company name, Carmat = Carpentier + Matra)
				Note : Internet showroom, available since June 2009
Cellectis	2000	IDF	Discovery, Therapy	Spin-off |	Genome	Preclin
		Romainville	(also Research, Subcontractor)	Managing Dir.-CEO: Choulika (André) [co-founder, born 1965, Ph.D. virology], also chairman
		(near Paris)	Key words: Genomic engineering, Meganuclease Recombination Systems (MRS), Proteins, DNA-repair	Oper.Dir.-COO: Simon (Mathieu) [M.D., ex-Wyeth, Pierre Fabre]
			Mission: to research in, develop and market rational genome engineering technologies with 3 focus, manufacturing of proteins for therapeutic purposes, improvement of seed characteristics and development of treatments against single-gene disorders (myopathies, sickle-cell anaemia, etc.) and against the infections by DNA viruses (herpes, viral hepatitis, HIV, etc.)	Sc.Dir.-CSO: Duchateau (Philippe) [Ph.D. science]
www.cellectis.com			Clients: Pharmaceutical industry, Biotechs, Agro industry, Research labs	Tech.Dir.-CTO: Epinat (Jean-Charles) [Ph.D. science, ex-Institut Pasteur]
			Competitors: Applied Biosystems, 454 Life Sciences, Celera	Fin.Dir.-CFO: Schwich (Pierre) [École des Mines (Paris), ex-Corning, Danone, Hewlett-Packard, 3i, Siparex, Next Venture)]
			Age: 21 year(s)	BusDev: Sourdive (David) [co-founder, Ph.D. virology, Polytechnique, ex-CEO]
				Lic.Dir.-CBO: Pollet (Dirk) [Ph.D. biochemistry (Antwerp), ex-Dircs Consultant, Galapagos, Glaxo Welcome, Innogenetics]
				Comm.Dir.: Delassus (Sylvie) [Polytechnique (1983), Ph.D., ex-Institut Pasteur, Aventis]
				Financers (Hist.): Kaminvest, BankInvest, AGF P.E., Odyssée, Edmond de Rothschild, FSI, Bastid, Public
				Note: website revamping, in September 2010
				note : the company has created a plant division in 2011, as a major diversification
Cellial Technologies	2001	North-Picardie	Contract, Research	Personal venture |	Multiple	Subcontractor
		Lens	Key words: CNS research optimization, In vitro cell culture, Blood-Brain Barrier	Managing Dir.-CEO: Leman (Sandrine) [born 1971, Ph.D., Institut Pasteur]
			Mission: accelerate CNS profiling and identify qualified leads candidates and eliminates the botleneck of drug transport accross Blood-Brain Barrier from clients’ discovery process	Sc.Dir.-CSO: Berezowski (Vincent) [Ph.D.]
			Clients: Pharmaceutical industry, Biotechs, Academic labs	Fin.Dir.-CFO:
www.cellial.com			Age: 20 year(s)	BusDev:
				Financers (Hist.): Finorpa, Nord Innovation, Innovam
				Note : 2 additional round-table financing in 2007 and 2008 of undisclosed amount
CellProthera	2008	Alsace	Discovery, Devices	Personal Venture |	Cardiovasc	Proof-of-Concept
		Mulhouse	Key words: Cell Therapy, Regeneration, Myocardial tissue	Managing Dir.-CEO: Lataste (Xavier) [born 1949, Ph.D. clinical neurochemistry, M.D., ex-Sandoz, Novartis]
			Mission: to develop innovative stem cell therapy for the regeneration of myocardial tissue, allowing prevention of chronic heart failure after myocardial infarction	Sc.Dir.-CSO: Hénon (Philippe) [founder, born 1938, M.D. Hematology, IRHT (founder, 1987), University Prof., also Board Chairman]
			Clients: not disclosed	Oper.Dir.-COO: Jelsch (Jean-Claude) [CNAM, MBA (CPA, Lyon), ex-Ecco, Adecco]
www.cellprothera.com			Age: 12 year(s)	Med.Dir.-CMO : Lataste (Xavier)
				Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): privately owned, Financière Bendelé, Alsace Business Angels (registered capital 2008 = 0.05 M€)
CellVax	2001	IDF	Contract, Services	Personal venture |	Cancers	Subcontractor
		Évry	Key words: Preclinical validation studies, Cancer, Viral diseases, Nodule, Angiogenesis model	Managing Dir.-CEO: Wei (Ming) [co-founder, born 1963, Ph.D. molecular biology]
		(near Paris)	Mission: to provide third parties with complete preclinical innovating services allowing to accelerate the drug development process in oncology field	Sc.Dir.-CSO: Wei (Ming)
			Clients: Pharmaceutical industry, Biotechs, Public-sector labs (up to phase II)	Med.Dir-CMO: Schatz (Christian) [M.D., Pharm.D., ex-Transgène]
www.cellvax-pharma.com			Age: 19 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)
				Notes : website again active in 2010 ; no press release (or news) since 2007
Cerenis Therapeutics	2004	Midi-Pyrénées	Discovery, Drugs	Personal venture |	Cardiovasc	Clinical
		Labège	Key words: HDL therapy, Cholesterol, Atherosclerosis, Cardiovasculars	Managing Dir.-CEO: Dasseux (Jean-Louis) [co-founder, born 1958, Ph.D., MBA, ex-Esperion Therapeutics (Pfizer), Fournier]
		(near Toulouse)	Mission: to discover, develop and market next generation HDL therapies	Oper.Dir.-COO: Brinkerhoff (William) [co-founder, MBA, ex-Esperion Therapeutics (Pfizer), Sankyo]
			Clients: Prescribers	Sc.Dir.-CSO: Lalwani (Narendra D.) [Ph.D., MBA, ex-Parke Davis, Esperion, Pfizer]
www.cerenis.com			Age: 16 year(s)	Fin.Dir.-CFO: Tupin (Cyrille) [CPA, ex-Sygnatures, PricewaterhouseCoopers]
				Med.Dir.-CMO: Paolini (John F.) [M.D., Ph.D., ex-Merck US, Bayer]
				BusDev: Brya (Tom) [MBA (Northwestern), MST, CPA, ex-Pharmacia, Monsanto/Searle, Cardinal Health, KV Pharmaceutical]
				Financers (Hist.): Sofinnova, HealthCap, Alta Partners, EDF Ventures, NIF Ventures, Daiwa Corporate Investment, TVM Capital, OrdiMed, FSI, Irdi-IXO
CliniGenetics	2000	Méditerranée	Discovery, Drugs	Personal venture |	Cardiovasc	Preclin
		Nîmes	Key words: Atherothrombosis, Atherix pig model, Alive bio-informatics	Managing Dir.-CEO: Falco (Jean-Louis) [born 1949, also board chairman, DEA Mkg-Finance Dauphine, ex-Schneider, Aurex (own consulting company)]
			Mission: to discover new therapeutics for the treatment of cardiovascular, cerebrovascular and lower limb ischemic diseases with a specific emphasis on atherothrombosis	Sc.Dir.-CSO: Marguerie de Rotrou (Gérard) [born 1940, Ph.D., ex-Inserm, CEA, University Professor in Functional Genomics]
			Clients: Prescribers	Fin.Dir.-CFO:
www.clinigenetics.com			Age: 20 year(s)	BusDev:
				Financers (Hist.): BankInvest
				Notes (February 2012) : the company website is unavailable and the URL does not exist any more since 2010, but a legal process with board meeting occurred in August 2010 (still the same, in September 2011) and a board meeting occured in December 2011 and an AGM in August 2012
Covalab	1995	Rhône-Alpes	Design, Drugs	Personal venture |	Multiple	Trade
		Villeurbanne	(also Design, Diagnostics)	Managing Dir.-CEO: El Alaoui (Saïd) [born 1955] & Thomas (Vincent) [born 1957]
		(near Lyon)	Key words: Immunochemistry, MABs, Polyclonal antibodies	Sc.Dir.-CSO:
			Mission: to supply innovative and unique polyclonal and monoclonal antibodies to third parties, such as universities, research institutes and commercial organisations around the world	Fin.Dir.-CFO:
www.covalab.com			Clients: Research labs	BusDev:
			Age: 25 year(s)	Financers (Hist.): privately owned (registered capital 2007 = 0.24 M€)
				Communication: no website corporate news since 2005
Cytheris	1999	IDF	Discovery, Immunology	Personal venture |	Cancers	Clinical
		Issy-les-Moulineaux	Key words: Immune modulation, Cancer, HIV, HCV, Recombinant interleukin	Managing Dir.-CEO: Marron (Damian) [born 1962, Pharmacologist, ex-3M Pharma, Orphan Europe, Rhône Poulenc Rorer, Glaxo, Nicox, Trophos]
		(near Paris)	Mission: to discover and develop new therapies for immune modulation, by reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT)	Sc.Dir.-CSO:
			Clients: Prescribers	Fin.Dir.-CFO: Vannier (Bertrand)
www.cytheris.com			Age: 22 year(s)	BusDev: Keatinge (Richard W.) [ex-BioAlliance Pharma]
				Financers (Hist.): Bioam, GestionT2C2/Bio, CDP Capital Technology Ventures, AXA P.E., Crédit Agricole P.E., CDC Innovation, Forbion, Caisse de dépôt et placement du Québec (Canada) (registered capital 2006 = 52.5 M€)
Cytoo	2008	Rhône-Alpes	Contract, Research	Personal venture |	Consumables	Trade
		Grenoble	Key words: Adhesive micropatterns, High Content Analysis, Cell based assays, Cell Screening	Managing Dir.-CEO: Chatelain (François) [co-founder, born 1965, ex-CEA, Protogene, Life Technologies, Genset, DNAgency]
			Mission: to develop, manufacture, and distribute products that make cellular analysis robust and reliable by drastically decreasing cell variability	Sc.Dir.-CSO: Bornens (Michel) [co-founder, board member, ex-Pasteur Institute, Curie Institute]
			Clients: Pharmaceutical industry	Oper.Dir.-COO: Fuchs (Alexandra) [co-founder, born 1969, Ph.D. biochemistry, Eng. Centrale, ex-CEA]
www.cytoo.com			Age: 12 year(s)	Fin.Dir.-CFO: Fayand (Laurence) [EM-Lyon (MBA), ex-Fideco, Hewlett-Packard, Alditech, Crocus Technology (co-founder), Beamind]
				BusDev: Sharp (William) [also President-CEO Cytoo Inc.]
				Financers (Hist.): privately owned (registered capital 2008 = 0.1 M€), Auriga Partners, CEA Valorisation, Rhône-Alpes-Création, Expansinvest, Jacques Lewinern, Sham and Entrepreneurs Fund
DBV Technologies	2002	IDF	Discovery, Diagnostics, Immunotherapy	Start-up (speciality pharma company) |	Allergy	Trade
		Boulogne Billancourt	Key words: Allergies, Viaskin, Epicutaneous Immunotherapy, Diallertest	Managing Dir.-CEO: Benhamou (Pierre-Henri) [born 1955, M.D. Paediatrics]
		(near Paris)	Mission: to develop an innovative non invasive delivery technology, Viaskin, worldwide patented, suitable for severe allergic patients to food allergy both in diagnosis and specific epicutaneous immunotherapy (EPIT)	Sc.Dir.-CSO: Benhamou (Pierre-Henri) (also, CEO) & Dupont (Bertrand) [Ensam]
			Clients: Pharmaceutical industry, Food industry, Cosmetics	Pharm.Dir.: Martin (Laurent) [Pharm.D., MBA IAE Paris, ex-Orphan Europe, Galderma, Fournier, Guerbet]
www.dbv-technologies.com			Age: 18 year(s)	Clin.Dir: Agbotounou (Wence) [Ph.D. pharmacology, MBA ESCP, ex-Quintiles, PRA International]
				Fin.Dir.-CFO: Schilansky (David) [Dauphine University, Imperial College London, ex-Ipsen, UBS Warburg, Thomson]
				Dvpt. Dir: Ruban (Charles) [ex-Stallergènes, Europgroup Centrale (Lyon), Ms.Sc, Biomedical Engineering (Harvard-M.I.T), MBA (INSEAD)
				BusDev:
				Financers (Hist.): Cap Décisif, Créagro, Sofinnova Partners, Apax Partners, ALK-Abello (Pharma company), InnoBio, Lundbeckfond Ventures, Shire, Alto Invest, Fonds Stratégique d’Investissement (FSI), Public
Diaxonhit	1997	IDF	Discovery, Diagnostics	Personal venture |	Genome	Trade
		Paris	(also, Discovery, Drugs)	Managing Dir.-CEO: Maurel (Loïc) [M.D., ex-Debiovision, Novartis, Rhône Poulenc Rorer]
			Key words: RNA splicing, Gene profiling technology, Cancer, Alzheimer	Sc.Dir.-CSO: Pando (Matthew) [Ph.D. molecular biology]
			Mission: to leverage on alternative RNA splicing, the process by which a single gene can lead to several proteins in the fields of drug discovery, diagnostics and biochips and to sell proprietary gene profiling technology named Datas in order to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease	Fin.Dir.-CFO: Duchesne de Lamotte (Hervé) [MBA, Ms (MIT), ex-Stanford Research Institute, AT Kearney France, IDM, Cirrus Finance Management]
www.diaxonhit.com			Clients: Pharmaceutical industry (own development up to phase II)	C.O.O.: (Diagnostics Division) Barber (Isabelle) [Ph.D. organic chemistry, ex-Isis Pharmaceuticals, Genset, Ortho Clinical Diagnostics (J&J)]
			Age: 23 year(s)	C.O.O.: (Therapeutic Division) Pando (Matthew) [Ph.D. molecular biology]
				BusDev:
				Comm.Dir.: Hoff (Corinne) [ex-Nicox, Aventis, Novartis)]
				Financers (Hist.): CDC Innovation, Sofinnova, Oxford Bioscience Partners, AGF P.E., BNP P.E., Dresdner Kleinwort, Danske Bank, LCF Ed. de Rotschild, Sudinnova, Biomérieux (5.8%, end 2007), Public
DNA Therapeutics	2006	IDF	Discovery, Drugs	Personal venture |	Cancers	Preclin
		Évry	Key words: Cancer, siDNA, DNA repair	Managing Dir.-CEO: Sun (Jian Sheg) [born 1959, also board chairman, Ph.D.]
		(near Paris)	Mission: to develop proprietary siDNA (signal interfering DNA) technology platform and molecules, interfering with DNA damage repair mechanisms, to fight treatment-resistant cancers	Sc.Dir.-CSO: Sun (Jian Sheg)
			Clients: Prescribers	Res.Dir.: Dutreix (Marie) [Ph.D, CNRS (Institut Curie)]
www.dna-therapeutics.com			Age: 14 year(s)	Fin.Dir.-CFO: Cervera (Bruno) [also, Actinnov (CEO), ex-Neurotech]
				BusDev:
				Financers (Hist.): Blue Medical Investment, Inserm Transfert
Domain Therapeutics	2001	Alsace	Discovery, Drugs	Personal venture |	CNS	Clinical
		Illkirch Graffenstaden	Key words: Neurological disorders, Neurotransmitter modulation, GPCR, Neuroclide, Glutamate inhibitor, Utrophin inducer, Parkinson, Alzheimer, Schizophrenia, Diabetes	Managing Dir.-CEO: Neuville (Pascal) [co-founder, born 1964, Ph.D. molecular biology, ex-Transgene, Assistant Professor]
		(near Strasbourg)	Mission: to discover and develop new treatments notably (but not only) for neurological and metabolic disorders, with an exclusive focus on GPCR-mediated neurotransmitter modulation	Sc.Dir.-CSO: Neuville (Pascal) & Bossi (Laura) [M.D. neurologist, ex-Sanofi, Synthélabo]
			Clients: Prescribers Pharmas and Biotechs (own development up to phase III Preclinical candidate)	Fin.Dir.-CFO:
www.domaintherapeutics.com			Age: 19 year(s)	BusDev:
				Financers (Hist.): Sofinnova Partners, Auriga Partners, La Compagnie Financière de Rothschild, Siparex, AGF P.E., FCJE, Airfi (Alsace Inter Regio Fonds d’Investissement) and Alsace Création, plus Sam Eletr and Bernard Gilly
				Communication: the company was named Faust Pharmaceuticals from inception till December 2008, with URL as www.faustpharma.com
Dynabio	1992	Méditerranée	Design, Diagnostics	Personal venture |	Multiple	Preclin
		Marseille	Key words: Stress proteins, Pancreatitis-Associated Protein (PAP), PancrePAP kit	Managing Dir.-CEO: Broto (Ruben) [born 1937]
			Mission: to develop new immunological tools to improve detection of Pancreatitis-Associated Protein (PAP), as a new class of stress proteins whose expression reflects with extreme sensitivity pathological alterations of several tissues in the gastrointestinal tract	Sc.Dir.-CSO:
			Clients: Research labs	Oper.Dir.: Slagel (Dean) [born 1970]
www.dynabio.com			Age: 28 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): privately owned
				Communication: no website news update since 2006, extremely limited media information since inception
Edelris	2005	Rhône-Alpes	Contract, Research	Spin-off |	Multiple	Subcontractor
		Lyon	Key words: Screening, Medicinal chemistry, Small molecules, Mimetics, CombiChem	Managing Dir.-CEO: Ortholand (Jean-Yves) [co-founder, born 1965, Ph.D., ex-Bayer, Rhône Poulenc Santé, Merck Santé]
			Mission: to design and produce innovative, therapeutically relevant, natural-mimetic screening compounds, in order to accelerate the hit-lead discovery process in pharmaceutical and biotech research organizations	Sc.Dir.-CSO: Greiner (Alfred) [co-founder, Ph.D., ex-Rhône Poulenc]
			Clients: Pharmaceutical industry	Fin.Dir.-CFO:
www.edelris.com			Age: 15 year(s)	BusDev:
				Financers (Hist.):
				Note: no legal accounting report since 2005
Endotis Pharma	2003	IDF	Discovery, Drugs	Start-up |	Multiple	Preclin
		Romainville	Key words: Small-glyco drugs (SGD), Thrombosis, Cancer	Managing Dir.-CEO: Woller (Charles) [born 1949, M.D., Ph.D. Clinical pharmacology, MBA, ex-Neuro3D (founder), Cadus, Roche France (Managing Director), Warner Lambert, Akzo]
		(near Paris)	Mission: to discover and develop Small-glyco drugs (SGD) for application in thrombosis and oncology	Sc.Dir.-CSO: Petitou (Maurice) [Ph.D., ex-Sanofi, Lauréat Prix Charles Mentzer 2009]
			Clients: Prescribers	Fin.Dir.-CFO: Degove (Stéphane) [Sup de Co (Paris), ex-Sanofi, Orica, OC&C]
www.endotis.com			Age: 17 year(s)	BusDev: Henrard (Denis) [Ph.D. biochemistry , also DHC, ex-BD Medical, Elixir Pharmaceuticals, Johnson & Johnson, Abbott]
				Financers (Hist.): Endeavour Vision, NIF SMBC Ventures, Sofinnova Partners
Epixis	2003	IDF	Discovery, Immunology	Personal venture |	Virus	Preclin
		Paris	Key words: Flu, C-Hepatitis, Mimetic particles, Virus-like particle vaccines	Managing Dir.-CEO: Dalba (Maria) [born 1967, M.D., Ph.D.]
			Mission: to develop a platform technology for a new generation of Virus-Like Particle vaccines (eVLP) that may allow to quickly manufacture seasonal or pandemic flu vaccines, to treat Hepatitis C, and to be applied to other infectious diseases, such as HPV or HIV	Sc.Dir.-CSO:
			Clients: Pharmaceutical industry	Fin.Dir.-CFO:
www.epixis.com			Age: 17 year(s)	BusDev:
				Financers (Hist.): Génopole 1er Jour
ERYtech Pharma	2004	Rhône-Alpes	Delivery, Drugs	Personal venture |	Cancers	Clinical
		Lyon	Key words: Encapsulation, Red blood cells, Cancer, Cleav’Ery, Oxygen’Ery, Deliv’Ery, Vaccin’Ery, Graspa	Managing Dir.-CEO: Beyen (Gil) [M.Sc. Bioengineering (Belgium), MBA, ex-TiGenix, Arthur D. Little] and Goineau (Pierre-Olivier) [co-founder, born 1967, MBA IAE Lyon, ex-KPMG]
			Mission: to develop the encapsulation of therapeutic molecules or enzymes into red blood cells in order to improve the therapeutic index, notably in orphan indications or underserved subpopulation of higher risk patients	Oper.Dir.:
			Clients: Prescribers	Sc.Dir.-CSO: Godfrain (Yann) [co-founder, born 1970, Ph.D., Biomedical Eng., ex-BioAlliance Pharma, Hemosystem, Hemoxymed]
www.erytech.com			Age: 16 year(s)	Pharm.Dir.: Bailly (David) [Pharm.Dr, Chem.Eng. (Montréal), ex-Skyepharma, Aguettant]
				Fin.Dir.-CFO:
				BusDev: Bouvier (Maud) [Sup de Co (Grenoble)]
				Financers (Hist.): AXA P.E., Auriga Partners, AGF P.E., Capdecisif, Créalys, Idinvest
Eye Tech Care	2008	Rhône-Alpes	Development, Devices	Personal venture |	Ophtalmology	Trade
		Rillieux la Pape (near Lyon)	Key words: Ultra-sounds, Ophthalmology, Glaucoma, EYEOP1	Managing Dir.-CEO: Romano (Fabrizio) [co-founder, born 1962, Vet.D., ex-Edap TMS]
			Mission: to develop a proprietary ultrasound-based procedure for treating eye diseases	Clin.Dir.: Farcy (Laurent) [co-founder, born 1973, Ms. biochemistry, ex-Medicrea, Sofradim]
			Clients: undisclosed	Indus.Dir.: Chapuis (Philippe) [co-founder, born 1968, Eng. ESEM Orléans, IAE, ex-Edap TMS]
www.eyetechcare.com			Age: 12 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): Crédit Agricole, CEA Valorisation, SHAM
Flamel Technologies	1990	Rhône-Alpes	Delivery, Drugs	Start-up |	Multiple	Trade
		Venissieux	(also, Design, Devices)	Managing Dir.-CEO: Anderson (Michael S.) [ex-Éclat Pharmaceuticals, KV Pharmaceutical, Ther-Rx Corporation, Schein, A.H. Robins Company]
		(near Lyon)	Key words: Polymer encapsulation, Interferon, Micropump, Medusa, Drug-protein delivery, Long Action	Sc.Dir.-CSO: Meyrueix (Rémi) [Ph.D., Eng. Physics, ex-Rhône Poulenc Santé] & Castan (Catherine) [Ph.D.]
			Mission: to improve the therapeutic characteristics, safety profile and ease of use of a wide variety of existing drugs, by using proprietary drug delivery platforms, Medusa for therapeutic proteins and peptides and Micropump for small molecules, with expertise in polymer chemistry	Oper.Dir.-COO: Jorda (Raphaël) [Ph.D., Eng. chemistry, ex-Rhône Poulenc Santé]
www.flamel.com			Clients: Pharmaceutical industry (own development up to pre-registration), Agrochemical industry	Fin.Dir.-CFO: Crouzet (Siân) [ex-McCormik, Ernst & Young]
			Age: 30 year(s)	BusDev: Lisi (Steven A.) [ex-Deerfield Mgt, Panacea Asset Mgt, Millenium Partners]
				Strat.Comm.Dir.: Mosseri Marlio (Charles)
				Financers (Hist.): Public (Nasdaq)
Fluofarma	2003	Aquitaine	Contract, Research (also, Contract, Services)	Spin-off |	Multiple	Subcontractor
		Bordeaux	Key words: High Content Screening (HCS), Automated flow cytometry, Cell-based assays	Managing Dir.-CEO: Pin (Jean-Baptiste) [founder, born 1974, ex-Ernst & Young Biotechnology]
			Mission: to provide third parties with High Content Screening (in-cellulo screening) services for target and drug discovery, predictive toxicity testing and cosmetics development	Sc.Dir.-CSO: Ichas (François) [Ph.D. biomedical sciences, ex-Inserm]
			Clients: Pharmaceutical industry, Biotech, Cosmetic industry	Sales&Mktg.Dir.: Plane (Julie) [ex-Avenium Consulting]
www.fluofarma.com			Age: 17 year(s)	Fin.Dir.-CFO:
				BusDev: Brisson (Bruno) [ex-Cellectis, Mauna Kea Technologies, Biospace Lab]
				Financers (Hist.): privately owned (registered capital 2006 = 0.24 M€)
GemacBio	1999	Aquitaine	Development, Diagnostics	Personal venture |	CNS	Trade
		Berganton, Saint Jean d’Illac	(also, Contract, Manufacturing)	Managing Dir.-CEO: Lurton (Louis) [born 1956]
		(near Bordeaux)	Key words: Antibodies, Customization, CNS disorders, Auto-immune diseases	Sc.Dir.-CSO:
			Mission: to develop a wide range of monoclonal and polyclonal antibodies against neurotransmitters, nitrosylated and nitrated amino-acids, bacterial antigens	Fin.Dir.-CFO:
www.gemacbio.com			Clients: Distributors, Pharmaceutical industry, Biotech, Research labs	BusDev:
			Age: 21 year(s)	Financers (Hist.): IRDI, ACI, SOCRI, Oséo/Anvar, business angels
				Note: the company website has ceased to provide with news since Fall 2009
Genepep	2003	Midi-Pyrénées	Contract, Research	Personal venture |	Multiple	Preclin
		St Jean de Védas	(also, Discovery, Drugs)	Managing Dir.-CEO: Puget (Karine) [co-founder, born 1970, Ph.D., ex-CNRS]
		(near Montpellier)	Key words: Peptides, Transcriptomes, Bio-informatics softwares	Sc.Dir.-CSO: Puget (Karine)
			Mission: to provide third parties with custom peptide synthesis, antibody production, peptide and protein sequencing, mass spectrometry, and to design own peptides for therapeutic research	Fin.Dir.-CFO: Chorro (Karine) [HEC (1994), also Deputy CEO]
www.genepep.com			Clients: Pharmaceutical industry (own development up to proof of concept)	BusDev:
			Age: 17 year(s)	Financers (Hist.): Sud Angels
Genewave	2001	IDF	Design, Devices	Personal venture |	Multiple	Trade
		Paris	Key words: Automated real-time micro-array, Hybridization imaging systems, Low-cost micro-array readers, HybLive	President: Desforges (François-Xavier) [born 1960, Ph.D. Electronics, ex-Photonetics]
			Mission: to develop, manufacture and market cutting-edge microarray instrumentation for diagnostic, clinical and life science research	Managing Dir.-CEO: Choumane (Houtaï) [Ph.D. Optics, also co-CEO]
			Clients: Research labs, Biotech, Other Institutions, OEM markets	Sc.Dir.-CSO: Weisbuch (Claude) [co-founder, born 1945, Ph.D. physics, Normale Sup, CNRS, University Professor (USA), ex-Bell Laboratories, Saint-Gobain, Thomson-CSF]
www.genewave.com			Age: 19 year(s)	Tech.Dir.-CTO: Rattier (Maxime) [Ph.D., Polytechnique, ex-Luxtera]
				Dev.Dir.: Marcy (Yann) [Ph.D., biological physics (Institut Curie)]
				Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.):
				Note: no legal accounting report since 2006, website contents much reduced in October 2012 (e.g. no more news)
Genfit	1999	North-Picardie	Discovery, Drugs	Start-up |	Cardiovasc	Clinical
		Lille	Key words: Cardiometabolic diseases, Dyslipidemia, Diabetes	Managing Dir.-CEO: Mouney (Jean-François) [co-founder, born 1955, Sup de Co (Paris), ex-M&M, also chairman]
			Mission: to bring therapeutic and diagnostic solutions to combat the major health concerns of diabetes, its associated risk factors, and its complications	Oper.Dir.-COO: Darteil (Raphaël) [Ph.D. molecular and cellular biology, ex-Aventis]
			Clients: Pharmaceutical industry	Sc.Dir.-CSO:
www.genfit.com			Age: 21 year(s)	Fin.Dir.-CFO: Huitorel (Nathalie) [Sup de Co (Lille), ex-MS Composites, Finuchem]
				BusDev:
				Financers (Hist.): Finorpa, Nord Cration, BP Création, Ya Global, University Lille II, Public
Genomic Vision	2004	IDF	Discovery, Drugs	Personal venture |	Multiple	Launch
		Paris	(also, Discovery, Diagnostics)	Managing Dir.-CEO: Bensimon (Aaron) [born 1957, co-founder, Ph.D. molecular biology, ex-Institut Pasteur]
			Key words: Diagnostics, Nanotechnology, DNA, Molecular combing	Sc.Dir.-CSO: Conseiller (Emmanuel) [Ph.D., ex-Sanofi-Aventis, Rhône-Poulenc Rorer]
			Mission: to develop novel diagnostic, biomarkers and drug discovery solutions based on proprietary nanotechnology for DNA analysis in the areas of cancer and acute diseases	Oper.Dir.-COO: Nerson (Daniel) [born 1958, co-founder, Ph.D., ex-Pasteur Mediavita, Dade-Behring]
www.genomicvision.com			Clients: Pharmaceutical industry (Sanofi-Aventis), Biotechs	Fin.Dir.-CFO: Martin (Erwan) [ex-Cytomics (co-founder), Syndex, Université de Marne la Vallée (Professeur, finances)]
			Age: 16 year(s)	BusDev: Abut (Fadilha)
				Financers (Hist.): Société Générale Asset Management Alternative Investments (SGAM AI), Vesalius BioCapital
GenoSafe	2003	IDF	Contract, Services	Start-up |	Multiple	Subcontractor
		Évry	Key words: Bio-therapeutics, Drug evaluation	Managing Dir.-CEO: Roques (Stéphane) [born 1972, SupdeCo, ex-Arthur Andersen, AFM, Genethon]
		(near Paris)	Mission: to evaluate the efficacy and safety of biotherapeutic products (viral and non-viral vectors, vaccines, recombinant proteins, monoclonal antibodies, cellular products …), for third parties	Sc.Dir.-CSO: Audit (Muriel) [Ph.D. Biology, ex-Genethon]
			Clients: Pharmaceutical industry, Biotechs, Research labs	Fin.Dir.-CFO:
www.genosafe.com			Age: 17 year(s)	BusDev: Zuliani (Vincent) [Ms. microbiology, ex-Genethon]
				Financers (Hist.): A2I (seed), Genethon, AFM
GenoScience Pharma	2001	Méditerranée	Discovery, Drugs	Personal venture |	Virus	Preclin
		Marseille	(also, Contract, Research)	Managing Dir.-CEO: (interim) Halfon (Philippe) [founder, born 1960, M.D., Ph.D., Alphabio (CEO)]
			Key words: Antivirals, Protease inhibitor, HCV	Sc.Dir.-CSO: Benech (Philippe) [Ph.D., ex-CNRS, founder Genesodi]
			Mission: to discover, develop and commercialize novel antiviral products (combining internal expertise in viral infections and unique molecular modeling through GenMol proprietary software (current focus on compounds for the treatment of hepatitis C infections)	Tech.Dir.-CTO: Pépé (Gérard) [Ph.D., Research Director (CNRS)]
www.3dgenoscience.com			Clients: undisclosed	Fin.Dir.-CFO: Corroy (Jean-Paul) [Sup de Co, ex-Alphabio]
			Age: 19 year(s)	BusDev:
				Financers (Hist.):
				Notes : no news on website since 2005 and URL changed from genosciencepharma.com back to old 3dgenoscience.com in 2011 ; legal data show a loss in capital in July 2011 (recurrent)
Genoscreen	2001	North-Picardie	Contract, Research	Spin-off |	Genome	Subcontractor
		Lille	Key words: DNA, Genome, Sequencing, Genotyping, Mutation detection, Gene expression, Microbial identification, Microbial typing	Managing Dir.-CEO: Tordeux (André) [born 1947]
			Mission: to develop and to realize innovative services on all kind of genomes to provide answers that best suit the needs of research laboratories, by using own high throughput equipments	Sc.Dir.-CSO: Tordeux (André), also Ferreira (Stéphanie) [Ph.D.]
			Clients: Pharmaceutical industry, Research labs, Life science industries, Academic research institutions	Sales Dir.: Antigny (Frédéric) [M.Sc., MBA]
www.genoscreen.fr			Age: 20 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): privately owned
GenOway	1999	Rhône-Alpes	Contract, Research	Spin-off |	Genome	Subcontractor
		Lyon	Key words: Gene amplification, Clonal animal, Mouse, Toxicology tests	Managing Dir.-CEO: Fraichard (Alexandre) [co-founder, born 1968, Ph.D. molecular biology (1997), Normale Sup (Lyon), MBA (HEC)]
			Mission: to provide third parties with customized and ready-to-use genetically modified mouse and rat models (Knock-out, conditional Knock-out, Knock-in, RNAi, humanized, transgenic mice and rats)	Sc.Dir.-CSO:
			Clients: Research labs	Fin.Dir.-CFO: de Poncins (Gilles) [co-founder, Science Po (Paris), MBA, ex-Renault, Qualis, Sofecome]
www.genoway.com			Age: 21 year(s)	BusDev: Thiam (Kader)
				Financers (Hist.): Dassault Développement, CDC E.I., Finoway (Qualis), Rhône Alpes Création, Public
Genticel	2001	Midi-Pyrénées	Discovery, Immunology	Spin-off |	Vaccines	Clinical
		Labège	Key words: Therapeutic vaccines, HPV, Cancer, Viral and bacterial infections, ProCervix	Managing Dir.-CEO: Timmerman (Ben) [founder, born 1959, Ph.D. Molecular Genetics, MBA, ex-Novartis Agro, Procordia]
		(near Toulouse)	Mission: to develop immuno-therapeutic products for the treatment of infection, neoplasia and cervical cancer, caused by Human Papillomavirus (HPV)	Sc.Dir.-CSO: Bissery (Marie-Christine) [Ph.D., Pharm.D., ex-Sanofi–Aventis, Rhône-Poulenc]
			Clients: Prescribers	Fin.Dir.-CFO: Koch (Martin) [Eng., MBA, ex-Eli Lilly, Cap Gemini, Elan, Zeneus, Cephalon]
www.genticel.com			Age: 19 year(s)	BusDev:
				Financers (Hist.): Institut Pasteur, FAM-Midi-Pyrénées, Edmond de Rothschild Investment Partners, IRDI, Amundi Private Equity Funds, InnoBio, FSI
				Note : from inception to February 2010, the company name has been BT Pharma (BT for Benedikt Timmerman, Founder)
GTP Technology	2000	Midi-Pyrénées	Contract, Manufacturing	Spin-off |	Multiple	Subcontractor
		Labège	(also, Design, Drugs)	Managing Dir.-CEO: Pease (Christopher) [born 1963, M.Sc. Insa (Lyon), ex-Millipore], also Managing dir. Darlington Life Science
		(near Toulouse)	Key words: In-vitro protein production, Gene work, Eiffel biostructure, L-lactis, Sensorines, Therapeutic protein, Cancers	Sc.Dir.-CSO: Ginisty (Hervé) [born 1971, Ph.D. molecular biology]
			Mission: to provide third parties with taylor-made solutions for the engineering and expression of recombinant proteins, and, to undertake own research on the L.lactis system for therapeutic proteins production	Oper.Dir.-COO: Devic (Éric) [founder, born 1966, Pharm.D., Ph.D. molecular biology], also chairman
www.gtptech.com			Clients: Pharma industry, Biotechs, Research labs	Tech.Dir.-CTO: Mozo (Julien) [Ph.D.]
			Age: 20 year(s)	Fin.Dir.-CFO:
				BusDev: Hountondji (Séverine) [M.Sc. Insa]
				Financers (Hist.): privately owned, undisclosed
Helios Biosciences	2002	IDF	Discovery, Targets (also, Contract, Research)	Academic |	Cancers	Preclin
		Romainville	Key words: Tissue expression, InSitu Hybridization, Biomarkers, Prostate cancer, Epilepsy, SIMPathway	Managing Dir.-CEO: Dumas (Jean-Baptiste) [founder, born 1958, Ph.D., ex-Genset, Genethon]
		(near Paris)	Mission: to research for own pipeline or to provide third parties with proprietary tools in the identification and characterization of therapeutic targets and biomarkers	Sc.Dir.-CSO: Dumas (Sylvie) [Ph.D., Normale Sup, ex-CNRS]
			Clients: Research labs, Cosmetic and Pharma industries	Fin.Dir.-CFO:
www.helios-bioscience.com			Age: 18 year(s)	Med.Dir.-CMO: Vujasinovic (Todor) [M.D., ex-CNRS]
				Financers (Hist.): privately owned (registered capital 2006 = 0.15 M€)
				Notes: no legal accounting report since 2006 ; the company is facing legal redress since September 12. 2012 ; URL has changed in 2012 from www.helios-biosciences.com to www.helios-bioscience.com (without ‘s’)
Hemarina	2007	Bretagne	Discovery, Drugs	Spin-off |	Blood	Preclin
		Morlaix	Key words: Hemoglobin, Blood-transfers, Transfusion, Sea-Invertebrate, Arenicole	Managing Dir.-CEO: Zal (Franck) [co-founder, born 1966, Ph.D. oceanography, ex-CNRS]
			Mission: to develop a new generation of oxygen-carrier for therapeutical and industrial applications (to help cope with the huge deficit of blood worldwide), based on extraction and purification from a marine organism	Sc.Dir.-CSO: Zal (Franck)
			Clients: Pharmaceutical industry (developement limited to early stage), Biotechs	Techn.Dir.-CTO: Rousselot (Morgane), [co-founder, Ph.D., Eng. ENSCMu, ex-GSK]
www.hemarina.com			Age: 13 year(s)	Pharm.Dir.: Naccache (Alain) [Pharm.Dr]
				Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): privately-owned, Inserm Transfert Initiative, Synergie Finance, Vaneau, and various business angels (registered capital 2007 = 0.26 M€)
Hybrigenics	1998	IDF	Discovery, Drugs	Academic |	Cancers	Preclin
		Paris	(also, Services, Research)	Managing Dir.-CEO: Delansorne (Rémi) [born 1959, Vet.D., Ph.D., ex-Theramex (Merck KgAa)]
			Key words: Protein-protein interaction, Cancer, Inecalcitol, D-vitamin, Protease inhibitor, Protein-interactions maps (PIMs), Ubiquitin	Oper.Dir.-COO: Formstecher (Etienne) [Polytechnique, Ph.D., also deputy CEO]
			Mission: to develop internal R&D programs on innovative target and therapeutics against cancer and to market proprietary high throughput technology and bioinformatics platforms focused on identification, validation and inhibition of protein interactions	Tech.Dir.: Rain (Jean-Christophe) [Ph.D. Molecular Genetics, co-founder, also deputy CEO]
www.hybrigenics-services.com			Clients: Prescribers	I.T.Dir.-CIO: Collura (Vincent) [Ph.D. structural bioinformatics]
			Age: 23 year(s)	Financers (Hist.): Medicis, Rendex, Sofindev, IMH, Lombard Odier, Alafi Capital, Life Science Partners, Banexi V.P., C.F. Edmond de Rothschild, Public
				note : in September 2012, the company changes its URL from www.hybrigenics.com to www.hybrigenics-services.com
Hyphen BioMed	1999	IDF	Design, Diagnostics	Personal venture |	Cardiovasc	Trade
		Neuville-sur-Oise	(also, Discovery, Diagnostics)	Managing Dir.-CEO: Amiral (Jean) [born 1952, Ph.D., Immunologist, Biochemist, ex-Serbio Stago (CSO)]
		(near Paris)	Key words: Research reagents, Thrombosis, Haemostasis, Auto-Immunity, Zymutest	Sc.Dir.-CSO: Vissac (Anne Marie) [born 1956, ex-Project Leader Serbio Stago]
			Mission: to develop a full line of innovative kits in diagnostic and research reagents and biochemicals, manual or automated, designed with clotting, chromogenic or immunological methods, for the exploration of Thrombosis, Haemostasis, Fibrinolysis and Auto-Immunity	Fin.Dir.-CFO:
www.hyphen-biomed.com			Clients: Research labs, Pharmaceutical industry	BusDev (& sales): Penissard (Véronique)
			Age: 21 year(s)	Financers (Hist.): privately owned, IDF Développement, Banque Populaire
Imagene	1998	Aquitaine	Contract, Manufacturing	Personal venture |	Genome	Trade
		Pessac	Key words: DNA-conservation, Encapsulation, Extraction	Managing Dir.-CEO: Tuffet (Sophie) [founder, Ph.D. biology]
		(near Bordeaux)	Mission: to provide third parties with high quality, long term preservation of DNA at room temperature for large scale genomic resources banks	Sc.Dir.-CSO:
			Clients: Research labs	Fin.Dir.-CFO:
www.imagene.fr			Age: 22 year(s)	BusDev:
				Financers (Hist.): OTC A.M. and Aquitaine Création Investissement
ImmunId	2005	Rhône-Alpes	Contract, Research	Personal venture |	Multiple	Trade
		Grenoble	Key words: Personalized diagnostics, Combinatorial Repertoire analysis, Immunology analysis, Immunodeficiency, Immuno-monitoring, T & B cell repertoire, Genomic DNA, Infectious diseases, Auto-immune diseases, Blood cancers, Lymphoma and Leukemia diagnosis, ImmunTracker, ImmunIg	Managing Dir.-CEO: Pasqual (Nicolas) [co-founder, born 1977, Ph.D. molecular biology, ex-CEA]
			Mission: to provide third parties with innovative diagnostic and prognostic tools and high value-added services to decrease clinical study costs by selecting better immuno-drug candidates and by measuring immuno-reconstitution and suppression kinetics	Sc.Dir.-CSO: Pasqual (Nicolas)
			Clients: Research labs, Hospitals, Pharmaceutical industry	Oper.Dir.-COO: Weisbuch (Sébastien) [born 1977, Ph.D. nanobiology, ex-CEA]
www.immunid.com			Age: 15 year(s)	Tech.Dir.-CTO: Mouret (Jean-François) [Pharm.D., ex-Applied Biosystems, Cogenics, Genome Express (co-founder)]
				Fin.Dir.-CFO:
				BusDev: Plantier (Nadia)
				Financers (Hist.): privately owned (registered capital 2006 = 0.053 M€)
				Note : website revamped in March 2009
Immutep	2001	IDF	Discovery, Immunology	Spin-off |	Cancers	Clinical
		Orsay	(also, Discovery, Diagnostics)	Managing Dir.-CEO: Hawken (John B.) [co-founder, born 1948, Ms. chemistry (Oxford), MBA, ex-Diatos, EntoMed, Neurotech, Aptanomics, Shell]
		(near Paris)	Key words: Cancer, Chronic Infectious Diseases, T Cell Immune responses, Immuno-therapy, MABs, Vaccines, Lag-3 protein	Sc.Dir.-CSO: Triebel (Frédéric) [co-founder, born 1954, M.D., Ph.D. immunology, ex-Inserm, Prof. Immunology, Paris University, Institut Gustave Roussy (IGR)]
			Mission: to develop immunostimulatory factors for the treatment of cancer and chronic infectious diseases and immunomodulatory therapeutic antibodies for the treatment of cancers or autoimmune diseases	Fin.Dir.-CFO:
www.immutep.com			Clients: Prescribers	BusDev:
			Age: 19 year(s)	Financers (Hist.): Innoven Partenaires, H2I
Imstar	1985	IDF	Contract, Services	Spin-off |	Studies	Subcontractor
		Paris	Key words: Microscopic imaging, Cell screening, Systems, Instruments, High throughput, Pathfinder	Managing Dir.-CEO: Soussaline (Françoise) [born 1945]
			Mission: to provide third parties with complete vertical solutions for fully automated high-throughput cellular analysis, in the fields of genotoxicity and environmental toxicity, focused on compound screening, biomonitoring, cytopathology, and dedicated to research, diagnostic, staging and drug discovery	Sc.Dir.-CSO: Soussaline (Françoise)
			Clients: Research labs	Fin.Dir.-CFO:
www.imstar.fr			Age: 35 year(s)	BusDev:
				Financers (Hist.): privately owned
In-Cell-Art	2005	Bretagne	Design, Delivery	Personal venture |	Multiple	Preclin
		Nantes	(also Discovery, Drugs)	Managing Dir.-CEO: Peyrot (Alain) [ex-Pharmacia, Sanofi, Mérieux, Wellcome, Wyeth]
			Key words: Supramolecular nanocarriers, Intracellular delivery, Polypeptide deficiencies, siRNA therapeutics, DNA vaccines, Antibodies production, In vitro transfection	Sc.Dir.-CSO: Pitard (Bruno) [co-founder, Ph.D., ex-Aventis Pasteur, Rhône Poulenc Rorer, CNRS, Inserm]
			Mission: to ascertain the delivery of a drug to the heart of the cell, the prolongation of its bioavailability, the vectorisation of DNA or RNA-based active principles	Oper.Dir.-COO: Belloc (Chloé) [born 1977, Ph.D., MBA]
www.incellart.com			Clients: Pharmaceutical industry, Biotechs, Academic labs	Fin.Dir.-CFO:
			Age: 15 year(s)	BusDev:
				Financers (Hist.): privately owned (registered capital 2006 = 0.05 M€)
Indicia Biotechnology	1998	Rhône-Alpes	Contract, Research	Personal venture |	Studies	Subcontractor
		Lyon	Key words: Microparticle technology, Immunoassay, Reagents, Luminex, OEM dosing methods, OEM production services	Managing Dir.-CEO: Legastelois (Stéphane) [born 1960, Ph.D. biochemistry, ex-Merck KgAa, Indicia Diagnostics]
			Mission: to provide third parties with solutions in R&D and manufacturing by providing a complete range of comprehensive services in the areas of immuno-diagnostics, microbiology and sterile reagents	Oper.Dir.-COO: Panier (Elodie) [Ms.Sc., Eng. IUP, DESS Management]
			Clients: Pharmaceutical industry, Diagnostics industry	Fin.Dir.-CFO:
www.indicia.fr			Age: 22 year(s)	BusDev:
				Financers (Hist.): privately owned (registered capital 2010 = 0.51 M€)
				Note : initial company registering under Indicia: 1984.03
InGen Biosciences	2001	IDF	Design, Diagnostics	Start-up |	Infections	Trade
		Chilly-Mazarin	Key words: Serology, In-vitro, Biomarkers, Infectious diseases, Bacterial antigens, Microbiology, Non-invasive testing, Capucine, Abag	Managing Dir.-CEO: Buckle (Isabelle) [Ph.D. microbiology, ex-Applied Biosystems, Ciphergen Biosystems, Amersham Pharmacia Biotech]
		(near Paris)	Mission: to design and manufacture protein biomarkers for multiparametric diagnostic in infectious diseases	Sc.Dir.-CSO: Mignon Godefroy (Karine) [Ph.D, ex-Chemunex, BMD, Bio-Rad]
			Clients: Pharmaceutical industry	Oper.Dir.-COO: Mollet (Patrick) [ex-Organon]
www.ingen.fr			Age: 19 year(s)	Mktg.Dir.: Martin (Jacques) [Eng. ESITPA, ex-Clonatec]
				Fin.Dir.-CFO: Elorga (Esteban) [Sup-de-Co, ex-Arhur Andersen]
				BusDev:
				Financers (Hist.): Innoven Partners, Société Générale A.M.
				Notes : Ingen website, acquired in 2006, updated with Ingen Biosciences (no company website ever as Abag) ; the company is subject of a take over in Novemebr 2012
Innate Pharma	1999	Méditerranée	Discovery, Drugs	Start-up |	Cancers	Clinical
		Marseille	Key words: Immuno-therapy, Immuno-modulators, Toll-like receptors (TLR), Cancer, IPH 4201	Managing Dir.-CEO: Brailly (Hervé) [co-founder, born 1961, Ph.D., ex-Immunotech-Beckman-Coulter]
			Mission: to develop first in class drugs targeting the innate immune system	Sc.Dir.-CSO: Romagné (François) [Ph.D., co-founder, ex-Immunotech-Beckman-Coulter]
			Clients: Prescribers	Clin.Dir.-CMO: Rozencweig (Marcel) [M.D., ex-BMS]
www.innate-pharma.com			Age: 21 year(s)	Fin.Dir.-CFO: Moukheibir (Catherine) [MBA, ex-Zeltia, Shire, Movetis]
				BusDev: Morel (Yannis) [Ph.D. oncology, NormalSup]
				Financers (Hist.): Sofinnova Partners, Auriga Partners, GIMV, Alta Partners, Gilde Biotech & Nutrition, Pechel Industries, Innoveris, Quilvest, NIF Ventures, Novo-Nordisk, Public
InnaVirVax	2008	IDF	Discovery, Immunology	Start-up |	HIV	Clinical
		Évry	(also, Discovery, Diagnostics)	Managing Dir.-CEO: Crouzet (Joël) [born 1958, Ph.D., Eng. Agro (Grignon), ex-Eurobiobiz, Inserm Transfert, Neurotech, APCells, Rhône-Poulenc Rorer]
		(near Paris)	Key words: HIV, CD4 restoration, Predictive test	Sc.Dir.-CSO: Crouzet (Joël)
			Mission: to develop a new HIV therapeutic vaccine aiming to restore CD4 to normal levels (without immunodeficiency) and to design a diagnostics test able to predict the evolution of the AIDS pathology of a given patient	Fin.Dir.-CFO:
www.innavirvax.fr			Clients: Pharmaceutical industry	Proj.Mgr.: Ho Tsong Fang (Raphaël) [Vet.D., Ph.D. microbiology and medical virology, ex-Institut Pasteur, UCLA (Los Angeles)]
			Age: 12 year(s)	Financers (Hist.): Pradeyrol Développement, Fa Dièse, CapDecisif Management, Genopole 1er Jour
Innovative Health Diagnostics	2009	Alsace	Discovery, Diagnostics (also, Contract, Research)	Personal venture |	Alzheimer,	Preclin
		Strasbourg	Key words: Alzheimer, Biomarkers, DiagAlz	Managing Dir.-CEO: Regnaut (Xavier) [co-founder, born 1964, Eng. Agro, Ms. Genetics, EMBA HEC]
			Mission: to develop and sell diagnostic solutions in the field of neurodegenerative diseases, based on detection of specific biological blood markers	Sc.Dir.-CSO: de Barry (Jean) [co-founder, Ph.D., Eng. Chemistry, ex-Inserm)
			Clients: Prescribers, Hospitals	Clin.Dir.-CMO: Sellal (François) [co-founder, M.D., Pharm.D., ex-CM2R]
www.ihdiag.com			Age: 11 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): privately owned (registered capital 2009 = 0.05 M€), Oseo, FEDER, Sodiv Alsace
				Note : IHD is the trade mark company name
IntegraGen	2000	IDF	Discovery, Diagnostics	Spin-off |	Cardiovasc	Launch
		Évry	Key words: Genes, Genomic mutations, Diabetes, Obesity, Bipolar disorders, Schizophrenia, Autism, GenomeHIP	Managing Dir.-CEO: Courtieu (Bernard) [born 1964, Vet.D., MBA, ex-Gemini Conseil, Ariba]
		(near Paris)	Mission: to research in gene targets and to market molecular diagnostics products and services that provide clinicians with new tools of personalized diagnosis, treatment, and therapy	Sc.Dir.-CSO: Liebaert (François) [MBA, ex-Schering, Abbott]
			Clients: Prescribers	Fin.Dir.-CFO: Riot-Lamotte (Laurence) [CESEM, ex-Aureus-Pharma, Deloitte & Touche, Thomson, Deutsche Telekom France]
www.integragen.com			Age: 20 year(s)	SalesMktg: Martin (Emmanuel) [Pharm.D., ex-Applied Biosystems]
				BusDev: Brady (David) [MBA, ex-Biogen-Idec, Lonza]
				Financers (Hist.): CDC Innovation, GenAvent, Bioam, Bay Tech, AGF P.E., Société Générale A.M., DSM
Ipsogen	1999	Méditerranée	Discovery, Diagnostics	Personal venture |	Cancers	Trade
		Marseille	Key words: Assays, Molecular expression, Biomarker, Blood cancer, Leukemia	Managing Dir.-CEO: Fert (Vincent) [co-founder, born 1959, Ms. immunology, ex-Immunotech, Beckman Coulter]
			Mission: to design, manufacture and market molecular assays with proven expertise in identifying and translating key discoveries into essential tests intented to support personalized approach to cancer treatment	Sc.Dir.-CSO: Hermitte (Fabienne) [co-founder, Ph.D., INA, ex-Rhône Poulenc, CNRS]
			Clients: Research labs, Prescribers	Oper.Dir.-COO: Debono (Stéphane) [born 1975, ESIM, ex-Immunotech, Beckman Coulter]
www.ipsogen.com			Age: 21 year(s)	Med.Dir.-CMO: Peyro-Saint-Paul (Hélène) [M.D. (Neurology), MBA (Essec), ex-B.M.S., Actelion, Serono]
				Fin.Dir.-CFO: Boissel (Pascale) [HEC, ex-Price Waterhouse Coopers, Danone, Lafarge]
				SalesMktg: Danan (Corinne) [ISC, MBA (Insead, 1990), ex-Monogram Biosciences, Eli Lilly]
				BusDev:
				Financers (Hist.): Samenar (Caisse d’Epargne), Institut Paoli-Calmettes, Société Générale A.M., Matignon Technologies, Innovéris, Connecticut Innovations, Viveris, Natixis, Octalia, Public
				Note : trade mark logo : «Ipsogen, cancer profiler»
I-Stem	2004	IDF	Discovery, Drugs	Start-up |	Multiple	Incub
		Évry	(also, Contract, Research)	Managing Dir.-CEO: Peschanski (Marc)
		(near Paris)	Key words: Stem cells, Monogenic diseases, Drug Discovery, Cell therapy, Pathological modelling, HTS & HCS	Sc.Dir.-CSO: Peschanski (Marc)
			Mission: to develop new treatments based on the potential offered by pluripotent stem cells (human embryonic cells and iPS) and applicable to rare diseases of genetic origin	Fin.Dir.-CFO: Zakhia (Raymond)
www.istem.eu			Clients: undisclosed	BusDev: Duprat (Sébastien) [born 1975, D.E.A. Biology, ex-ESTOOLS, Scientific Research Helsinki-Lille]
			Age: 16 year(s)	Financers (Hist.): INSERM, AFM (French Muscular Dystrophy Association)
				Note : a public-private Institute equally funded by INSERM and AFM, on a yearly budget (about 7 M€ each year between 2005 and 2008)
Karcinolys	2005	Rhône-Alpes	Development, Drugs	Start-up |	Cancers	Incub
		Lyon	Key words: Biologicals, Liver cancer, Pancreatic cancer, Herpes virus	Managing Dir.-CEO: Béjot (Jean-Luc) [born 1957, M.D., ex-OPI, Novartis, Quintiles, Genzyme, Ipsen, Cassenne]
			Mission: to develop a new generation of tumour-selective «replication conditional» HSV-1 derived oncolytic viruses	Sc.Dir.-CSO:
			Clients: Pharmaceutical industry	Fin.Dir.-CFO:
www.no-website.net			Age: 15 year(s)	BusDev:
				Financers (Hist.): privately owned (registered capital 2009 = 0.1 M€)
				Communication : no website, yet
Keosys	2001	Bretagne	Development, Devices	Start-up |	Cancers	Trade
		Saint Herblay (near Nantes)	Key words: Nuclear medicine, Digital imaging, Radiology, Mammography, I.T. programmes, Visio+, Positoscope	Managing Dir.-CEO: Fortineau (Jérôme) [born 1968, co-founder, Eng., ex-Alcatel]
			Mission: to develop new imaging and communication systems for nuclear medicine and radiology	Sc.Dir.-CSO: Terve (Pierre)
			Clients: Distributors or directly to Hospitals, Clinics, Cancer centers, Radiologists	Fin.Dir.-CFO:
www.keosys.com			Age: 20 year(s)	BusDev:
				Financers (Hist.): Lumiplan, Vizille Capital Innovation (CIC group), Pays de Loire Développement, Sodera
				Note: no legal accounting report since 2007
MABlife	2000	IDF	Discovery, Drugs	Personal venture |	Cancers	Clinical
		Évry	Key words: MABs, Antibody-based therapeutics, Cancer, Immuno-therapy, Angiogenesis	Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)]
		(near Paris)	Mission: to develop proprietary antibody-based therapeutics for the treatment of cancer	Sc.Dir.-CSO: Boumsell (Laurence)
			Clients: Pharmaceutical industry (own development up to phase II included)	Fin.Dir.-CFO: vacant
http://www.mablife.com			Age: 20 year(s)	BusDev: vacant
				Financers (Hist.): Génopole 1er Jour, IxCore, Anvar
				Notes : full company legal name is Monoclonal Antibodies Therapeutics, up to 2011 ; previous URL was www.matbiopharma.fr ;
Magnisense	2003	IDF	Discovery, Diagnostics	Start-up |	Point of Care Testing	Trade
		Rosny-sous-Bois (near Paris)	Key words: Magnetic immunoassays, In-vitro diagnostics, Point-of-Care, Rapid tests, Super-paramagnetic particles, Magnetic detection, Portable reader, Cardiac markers, Infections, MIAtek, MIAstrip, MIAflo	Managing Dir.-CEO: Lenglet (Luc) [born 1964, Ph.D., Normale Sup (Paris), ex-Rhodia, Arthur D. Little]
			Mission: to develop and market next-generation magnetic immunoassays that improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing (immunoassays that are based on magnetic bead markers, which can be used to achieve the accuracy of laboratory testing with the ease of use of rapid test methods)	Sc.Dir.-CSO: Nikitin (Petr) [Ph.D.]
			Clients: Diagnostic industry	Fin.Dir.-CFO:
www.magnisense.com			Age: 17 year(s)	RegMktg: El Yousfi (Hayat) [Mme, Pharm.D.]
				BusDev: Péquignot (Clayton) [Ms. Biotechnology, ex-Cap Gemini Ernst and Young, Venstrata]
				Financers (Hist.): Baring Vostok Capital Partners, Psilos Group, Seventure, Creadev (registered capital 2007 = 0.1 M€)
				Note : legal foundation, February 20. 2007 (not 2003, as per company)
Mapreg	2000	IDF	Discovery, Drugs	Academic |	CNS	Clinical
		Le Kremlin-Bicêtre	Key words: Microtubules, CNS diseases, Spinal cord injury, Traumatic brain injury, Neurosteroids	Managing Dir.-CEO: Baulieu (Etienne Emile) [born 1926, M.D., Ph.D.]
		(near Paris)	Mission: to dscover new drugs based on a novel mechanism for the protection and repair of nerve connections	Managing Dir.-CEO (co-): Villey (Isabelle) [Ph.D., MBA, ex-Vision Institute]
			Clients: Pharmaceutical industry (own development up to phase II included)	Sc.Dir.-CSO: Robel (Paul) [M.D.]
www.mapreg.com			Age: 20 year(s)	Oper.Dir.-COO: Baeuerle (Ralf) [PhD]
				Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.):
				Note: according to the company (November 2012, but website not regularly updated), total raised capital is close to 5 M€.
Mauna Kea Technologies	2000	IDF	Discovery, Diagnostics	Personal venture |	Multiple	Trade
		Paris	Key words: Fluorescence, Fiber optic, Microscopy, Pneumology, Gastrology, CellVizio	Managing Dir.-CEO: Loiseau (Sacha Alexandre) [co-founder, born 1970, Ph.D., Eng. École Polytechnique, ex-CNES]
			Mission: to develop in vivo cellular imaging systems for biomedical and medical applications	Sc.Dir.-CSO: Lacombe (François) [Ph.D. astrophysics, Normale Sup]
			Clients: Specialist doctors	Fin.Dir.-CFO: Cohen (Éric) [MBA, ex-Biocortech, Hybrigenics, Teva, Radio BFM]
www.maunakeatech.com			Age: 20 year(s)	BusDev:
				Financers (Hist.): Psilos Group, Seventure, CreAdev
Medesis Pharma	2003	Langeudoc-Roussillon	Discovery, Drugs	Personal venture |	Multiple	Clinical
		Baillargues	Key words: Nanotechnology drug delivery systems, Metals low doses, Vanadium, Manganese, Strontium, Metabolic syndrome, Diabetes, Huntington Disease, Bipolar Disorders	Managing Dir.-CEO: Maurel (Jean-Claude) [founder, born 1946, M.D., M.Sc., ex-Natura Medica (founder)]
		(near Montpellier)	Mission: to develop new innovative treatments of diabetes and neurodegenerative disorders based on metallic ions technology and delivery of nucleic acid (siRNA antisens)	Sc.Dir.-CSO: Maurel (Patrick) [Ph.D., ex-Inserm]
			Clients: undisclosed	Oper.Dir.-COO: Jackson (Peter) [Ph.D.]
www.medesispharma.com			Age: 17 year(s)	Fin.Dir.-CFO:
				BusDev: Jackson (Peter)
				Financers (Hist.): privately owned
Mellitech	2005	Rhône-Alpes	Discovery, Drugs	Spin-off |	Cardiovasc	Preclin
		Grenoble	(also, Design, Diagnostics)	Managing Dir.-CEO: Platford (Richard) [Ms. mechanical sciences (Cambridge), MBA (LBS), ex-PricewaterhouseCoopers, Cellvir]
			Key words: Type 2 diabetes, Zinc transporter protein	Sc.Dir.-CSO: Chimienti (Fabrice) [Ph.D.]
			Mission: to develop a new therapeutic and diagnostic approach to type II diabetes based on a proprietary (PCT) zinc transporter protein, only present in insulin-secreting cells	Oper.Dir.-COO: Girod-Roux (Pierre-Marie) [also board chairman, DEA (Physiology), Ms. management]
www.mellitech.com			Clients: undisclosed	Fin.Dir.-CFO:
			Age: 15 year(s)	BusDev: de Boysson (Yann) [co-founder, Engineer]
				Financers (Hist.): privately owned (registered capital 2006 = 0.08 M€)
Metabolys	2008	Rhône-Alpes	Contract, Research	Spin-off |	Testing	Proof-of-Concept
		Lyon	Key words: Metabolomics, Toxicity, Drug candidate	Managing Dir.-CEO: Baverel (Gabriel) [born 1947, founder, M.D., University Prof. Lyon]
			Mission: to improve the preclinical evaluation of drug candidates through cellular metabolomics in pharmacology, toxicology and nutrition (identification and quantification of metabolic pathways by the combination of enzymatic and carbon 13 NMR measurements with mathematical models of metabolic pathways)	Sc.Dir.-CSO: Baverel (Gabriel)
			Clients: Pharmaceutical industry, Research labs	Fin.Dir.-CFO:
www.metabolys.org			Age: 12 year(s)	BusDev:
				Financers (Hist.): privately owned (registered capital 2008 = 0.15 M€)
				Note: web site, still under construction since inception (May 2011)
MilleGen	1999	Midi-Pyrénées	Contract, Manufacturing	Personal venture |	Multiple	Subcontractor
		Labège	(also, Development, Drugs)	Managing Dir.-CEO: Kharrat (Abdel Hakim) [co-founder, born 1961, Ph.D. biology, Ms. Management, ex-EMBL Heidelberg]
		(near Toulouse)	Key words: Directed Molecular Evolution (DME), MutaGen, Mutascreen, Gene cloning, High throughput screening, Antibodies, Peptides	Sc.Dir.-CSO: Bouayadi (Khalil) [co-founder, Ph.D. molecular pharmacology]
			Mission: to develop and and genetically engineer new human therapeutic antibodies based on proprietary Directed Molecular Evolution platform, for third parties and for own pipeline (also, to offer custom services including high-throughput DNA sequencing, bioinformatics, gene cloning and vector development services, peptides synthesis and antibodies engineering and production)	I.T.Dir.-CIO: Crozet (Fabien) [Ph.D. molecular neurobiology]
www.millegen.com			Clients: Pharmaceutical industry, Research labs, Biotechs	Fin.Dir.-CFO:
			Age: 21 year(s)	BusDev: Deflisque (Anne) [Ms. biochemistry, ex-GE Healthcare]
				Financers (Hist.): privately owned (registered capital 2006 = 0.07 M€)
Murigenetics	2005	Méditerranée	Discovery, Drugs	Personal venture |	Genome	Preclin
		Marseille	Key words: Genetic diseases, Charcot-Marie-Tooth (CMT), Hereditary neuropathy, Genetic mental disorders	Managing Dir.-CEO: Berro (Marine) [born 1980, ESIL]
			Mission: to develop new drugs for the treatment of serious genetic diseases, based on internal production of genetically modified animal models expressing human genes of patients with hereditary peripheral neuropathies, or mental retardation	Sc.Dir.-CSO:
			Clients: Prescribers	Fin.Dir.-CFO:
www.murigenetics.com			Age: 15 year(s)	BusDev:
				Financers (Hist.): grants by Association Française pour le traitement de la Myopathie (AFM, i.e. French Muscular Dystrophy Association), privately owned (registered capital 2006 = 0.04 M€)
				Note : on legal accounts, company have only 1 headcount in 2010 ; at the end of 2011, legal accounts mention 2 headcounts, no revenues and major deficits ; in November 2012, the company website is inactive and the URL dropped
NanoBiotix	2003	IDF	Design, Drugs	Personal venture |	Cancers	Clinical
		Paris	Key words: Nanoparticles, Cancer, NanoXray, Nbtxr3	Managing Dir.-CEO: Levy (Laurent) [co-founder, born 1971, Ph.D. physical chemistry, ex-Altran]
			Mission: to develop new cancer treatments based on proprietary NanoXray platform, as an injection of patented X-ray activated nanoparticles	Sc.Dir.-CSO:
			Clients: Hospitals	Oper.Dir.-COO: Boussaha (Kader) [co-founder, born 1973, Eng. ENI, ex-Altran]
www.nanobiotix.com			Age: 17 year(s)	Med.Dir.: Borghi (Elsa) [M.D., ex-Sanofi-Aventis]
				Fin.Dir.-CFO:
				BusDev: Mühlenweg (Bernd) [Ph.D. chemistry, Munich, ex-Wilex]
				Financers (Hist.): Cap Décisif, Amorçage Rhône Alpes, Matignon Technologies, OTC Asset Management
				Note: an IPO is being prepared in Fall 2012
Neorphys	2005	Méditerranée	Discovery, Drugs	Personal venture |	Multiple	Preclin
		Nîmes	Key words: Nausea-free acute pain, Morphine derivatives, Opioids, Analgesics	Managing Dir.-CEO: Lahana (Roger) [co-founder, born 1954, ex-Syntem]
			Mission: to develop a new family of opioid analgesic drug candidates with low side effects	Sc.Dir.-CSO:
			Clients: Pharmaceutical industry (own development up to phase IIb)	Oper.Dir.-COO: Larbouret (Karine) [co-founder, ex-Syntem]
www.neorphys.com			Age: 15 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): Soridec, Inserm-Transfert, CEA Valorisation, Fa Diese 2, Seillans, plus independent business angels
Neovacs	1993	IDF	Discovery, Immunology	Spin-off |	Cancers	Clinical
		Paris	Key words: Therapeutic vaccines, Cancer, Inflammatory diseases, Antibodies, Kinoids, Toxoids	Managing Dir.-CEO: Fanneau de la Horie (Guy-Charles) [born 1959, Vet.D., MBA, ex-IDM, Biogen (President Europe), Schering-Plough]
			Mission: to develop anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases	Sc.Dir.-CSO: Grouard-Vogel (Géraldine) [Pharm.D., Ph.D. immunology, ex-Aventis Pasteur, Walter Reed Army Institute]
			Clients: Prescribers	Pharm.Dir.: Fanget (Bernard) [ex-Flamel, Sanofi Pasteur]
www.neovacs.com			Age: 27 year(s)	Fin.Dir.-CFO:
				BusDev: Whitehead (Piers) [Oxford, ex-VaxGen, Mercer Management Consulting]
				Comm.Dir.: Hocdée-Leroy (Florence) [EM Lyon, ex-Rhône-Poulenc, KBC Securities, Grosvenor]
				Financers (Hist.): Truffle Ventures, Europe Innovation, Debiopharm, Novartis, OTC Asset Management
				note : at the end of December 2010, Novartis shares account for 26.6%
Netris-Pharma	2008	Rhône-Alpes	Discovery, Drugs	Personal venture |	Cancers	Proof-of-Concept
		Lyon	Key words: Breast cancer, Metastasis, Dependence receptors, Targeted Therapy	Managing Dir.-CEO: Bernet (Agnès) [co-founder, born 1968, CNRS]
			Mission: to develop therapeutic compounds for the treatment of cancer, in particular of breast cancer and NSC Lung cancer	Sc.Dir.-CSO: Bernet (Agnès)
			Clients: undisclosed	Fin.Dir.-CFO:
www.no-website.net			Age: 12 year(s)	BusDev:
				Financers (Hist.): privately owned (registered capital 2009 = 0.04 M€)
Neuronax	2003	Centre	Discovery, Drugs	Spin-off |	CNS	Proof-of-Concept
		Saint Beauzire	(also Contract, Services)	Managing Dir.-CEO: Gobron (Stéphane) [born 1968]
		(near Clermont-Ferrand)	Key words: Neural repair, Parkinson disease, Ataxy, NX peptides	Sc.Dir.-CSO: Gobron (Stéphane)
			Mission: to develop new drugs for neural repair in cases of neuro-traumas and neuro-degenerative disorders	Fin.Dir.-CFO:
www.neuronax.com			Clients: Pharmaceutical industry (out-licensing after proof-of-concept)	BusDev:
			Age: 17 year(s)	Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)
NewVectys	2010	IDF	Contract, Research	Personal venture |	Multiple	Preclin
		Paris	Key words: Gene-Transfer, Vectorology, Translational-Research, Gene-Therapy, Transgenic-Models	Managing Dir.-CEO: Duboscq (Antoine) [co-founder, born 1968, ex-Procter & Gamble, Boston Consulting Group, WMI]
			Mission: to develop innovative gene transfer technologies and their applications in transgenic large animal models and gene therapy (own research and co-development as subcontractor)	Sc.Dir.-CSO: Sarkis (Chamsy) [co-founder, born 1974, Ph.D., ex-CNRS]
			Clients: Pharmaceutical industry, Medical devices industry, Biotechs and CROs	Fin.Dir.-CFO:
www.newvectys.com			Age: 10 year(s)	BusDev:
				Financers (Hist.): privately owned (registered capital 2011 = 0.25 M€)
NicOx	1996	Méditerranée	Delivery, Drugs	Start-up |	Multiple	Pre-reg
		Nice	Key words: Nitric oxide, Inflammation, Cardio-metabolic, Osteo-arthritis	Managing Dir.-CEO: Garufi (Michele) [co-founder, born 1954, Pharm.D., ex-Recordati, Italfarmaco]
			Mission: to develop and market investigational nitric oxide-donating drugs to meet unmet medical needs, based on proprietary nitric oxide-donating technology	Sc.Dir.-CSO: Pfister (Pascal) [M.D., Pharm.D., ex-Novartis, Sandoz]
			Clients: Prescribers	Fin.Dir.-CFO: Castaldi (Eric)
www.nicox.com			Age: 24 year(s)	BusDev: Spencer (Gavin) [Ph.D. chemistry, ex-Novartis, Boots]
				Financers (Hist.): Apax Partners, Sofinnova, European Medical Ventures, Paribas P.I., Health Capital AB, Oppenheimer Funds, QVT Fund, AQR Capital Management, Pfizer Overseas, Baker Brothers Investments, Public, Managers (less than 3% in 2008)
Nokad	2004	IDF	Discovery, Targets	Personal venture |	Studies	Trade
		Évry	Key words: Secreted proteins inactivation, Functional knock-out, Protein vaccination, Mammals	Managing Dir.-CEO: Abina (Amine, Mohammed) [co-founder, born 1963, M.D. immunology, Ph.D., ex-AFSSAPS]
		(near Paris)	Mission: to develop and market functional inactivation (knock-out) of secreted endogenous proteins in mammals, through direct in vivo induction of a specific immune response against an endogenous target	Sc.Dir.-CSO: Erard (François) [Ph.D., University Professor, ex-Novartis]
			Clients: Pharmaceutical industry, Research labs	Fin.Dir.-CFO:
www.nokad-technology.com			Age: 17 year(s)	BusDev:
				Financers (Hist.): Cap Décisif and Genopole 1er Jour, SHAM (Société Hospitalière d’Assurances Mutuelles), privately owned
Nosopharm	2009	Méditerranée	Discovery, Drugs	Personal venture |	Infections	Proof-of-Concept
		Nîmes	Key words: Anti-infectives, Clostridium difficile, Multi-resistant Gram-negative pathogens	Managing Dir.-CEO: Villain-Guillot (Philippe) [co-founder, born 1977]
			Mission: to discover and develop novel antibiotics against nosocomial and emerging infections	Sc.Dir.-CSO: Gualtieri (Maxime) [co-founder, ex-CNRS]
			Clients: Biotechs, Pharmaceutical industry (own development up to phase I)	Fin.Dir.-CFO:
www.nosopharm.com			Age: 11 year(s)	BusDev:
				Financers (Hist.): privately owned (registered capital 2009 = 0.02 M€)
NovAliX	2002	Alsace	Discovery, Drugs	Spin-off |	Multiple	Preclin
		Strasbourg-Illkirch	(also Design, Protein)	Managing Dir.-CEO: Zeyer (Denis) [born 1972, Ph.D., ex-IGBMC]
			Key words: NHR (Nuclear Hormone Receptors), Ligands, Protein crystallography, Cancer, Type II diabetes, Obesity, Early-stage	Sc.Dir.-CSO: Zeyer (Denis)
			Mission: to discover, from early-stage, drugs based structure-based design using X-ray crystallography, with a main interest in nuclear hormone receptors, for cancers, type II diabetes, obesity and other metabolic diseases, also for neglected diseases such as schistosomiases, and to provide third parties with service activities in protein crystallization protein crystallography, and ligand screening using mass spectrometry	Fin.Dir.-CFO:
www.alix-pharma.com			Clients: Research labs	BusDev:
			Age: 18 year(s)	Financers (Hist.): privately owned (registered capital 2006 = 0.07 M€)
				Note: Alix has become, end of 2008, a subsidiary of Novalix, then Alix has been discontinued in 2009 ; no legal reports since 2006 for Novalix (and also Alix) ; Jenn (Stephan) [born 1968] is president of the company
NovoCIB	2005	Rhône-Alpes	Contract, Research	Personal venture |	Virus	Subcontractor
		Lyon	(also, Discovery, Drugs)	Managing Dir.-CEO: Godard (Nicolas) [Ms. microbiology (INA), MBA]
			Key words: Nucleotides, Antivirals, HCV, Enzymes, Precice platform	Sc.Dir.-CSO: Balakireva (Larissa) [founder, born 1966, Ph.D. Cell Biology, ex-IBS], also President
			Mission: to provide third parties with a wide range of products and services, as nucleoside kinase phosphorylation assays, IMPDH or PNP inhibition assays, nucleotides and nucleosides bio-analysis, in cell extract or body fluids (including clinical samples) or the evaluation of the metabolic impact of compounds intended for therapeutic applications in oncology and virology or as immunosuppressive agents, and to develop own anti-viral nucleoside analogues	Fin.Dir.-CFO:
www.novocib.com			Clients: Pharmaceutical Industry, Biotechs	BusDev:
			Age: 15 year(s)	Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)
Novotec	1997	Rhône-Alpes	Contract, Manufacturing	Spin-off |	Multiple	Subcontractor
		Lyon	Key words: Antibodies, Extra cellular matrix (ECM), Tissue-samples, Immunochemistry, Histology	Managing Dir.-CEO: Guerret (Sylviane) [born 1950] et Hartmann (Danielle) [born 1953]
			Mission: to develop, produce and distribute species specific antibodies directed against macro-molecules of the Extracellular Matrix (ECM), to prepare tissue analysis	Sc.Dir.-CSO: Hartmann (Daniel)
			Clients: Pharmaceutical industry, Cosmetic industry, Biotechs, Academic and Industry Research labs	Fin.Dir.-CFO:
www.novotec-labs.com			Age: 23 year(s)	BusDev: Prulière (Franck)
				Financers (Hist.): privately owned (registered capital 2006 = 0.065 M€)
				Note: no communication policy on web site
Obe Therapy	2000	IDF	Discovery, Targets	Personal venture |	Cardiovasc	Preclin
		Évry	(also, Discovery,, Drugs)	Managing Dir.-CEO:
		(near Paris)	Key words: Gene targets, Intestine, Obesity, Hyper-cholesterolemia, Type II diabetes	Sc.Dir.-CSO: Harosh (Itzik Isaac) [founder, born 1954, Ph.D., ex-GlaxoWelcome, CNRS, Technion (Israel)] and Braud (Sandrine) [also COO, Ph.D., ex-CEA, Institut Pasteur]
			Mission: to discover new targets and to develop new drugs for obesity, hypercholesterolemia and type II diabetes, based on the identification of gene targets associated with a lean phenotype	Fin.Dir.-CFO:
www.obetherapy.com			Clients: Pharmaceutical industry	BusDev:
			Age: 21 year(s)	Financers (Hist.): privately owned (registered capital 2006 = 0.06 M€)
				Note: no communication policy on web site
Oligovax	2000	IDF	Discovery, Immunology	Start-up |	Cancers	Clinical
		Paris	Key words: Oligo-nucleotides, Immuno-stimulants, Cancer, Liténimod	Managing Dir.-CEO: van der Schueren (Paul) [founder, born 1963, MBA]
			Mission: to develop innovative anti-cancer therapies belonging to a new therapeutic class, TLR9 agonists	Sc.Dir.-CSO: Richard (Margaretha) [Pharm.D., ex-Pierre Fabre, AP-HP]
			Clients: Prescribers	Fin.Dir.-CFO:
www.oligovax.com			Age: 20 year(s)	BusDev:
				Financers (Hist.): Global Millenium Fund
				Communication: no website news update since 2006, no legal information available since end 2005
				Note : webhosting with Lycos withdrawn in March 2009
Oncodesign	1995	Rhône-Alpes	Contract, Research	Personal venture |	Studies	Subcontractor
		Dijon	(also, Discovery, Therapies)	Managing Dir.-CEO: Genne (Philippe) [co-founder, born 1961, Ph.D.]
			Key words: In-vivo screening, Nude-rat, Cancer, Drug resistance, Translational research, Neurology	Sc.Dir.-CSO:
			Mission: to provide third parties with preclinical evaluation of novel anticancer therapeutics and to identify and validate molecular targets involved in cancer pathologies	Fin.Dir.-CFO:
www.oncodesign.fr			Clients: Pharmaceutical industry	BusDev: Ewing (Jonathan)
			Age: 25 year(s)	Financers (Hist.): CDC, Avenir Entreprise Gestion, Banque de Vizille
OriBase Pharma	2007	Méditerranée	Contract, Research	Personal venture |	Studies	Subcontractor
		Montpellier	Key words: Computational chemistry, Predictive-interpretative model building, QSAR/QSPR datamining, Structure-Activity relationships, SARA platform	Managing Dir.-CEO: Yasri (Aziz) [co-founder, born 1966, Ph.D. biophysics and drug sciences, ex-Syntem, ArQule, J&J, Nova Decision]
			Mission: to provide third parties with medicinal chemistry oriented tools and services (chemo-informatics, molecular modelling and bio-informatics) from Hit Identification to Lead Optimisation	Sc.Dir.-CSO: Yasri (Aziz)
			Clients: Pharma industry, Agro industry, and Biotechs	Chem.Dir.: Cazals (Bénédicte) [Ph.D. organic chemistry, ex-Idenix, Azasynth]
www.oribase-pharma.com			Age: 13 year(s)	I.T.Dir.: Chevé (Gwénaël) [Ph.D. medicinal chemistry, ex-Pierre Fabre]
				Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): privately owned
				Notes : in December 2010, the initial websites of the forming companies are still active under www.novadecision.com and www.azasynth.com ; foundation date of Oribase Pharma selected as that of Azasynth, i.e. only 1 month before Nova Decision
Oroxcell	2004	IDF	Contract, Services (also, Delivery, Drug)	Personal venture |	Studies	Subcontractor
		Romainville	Key words: Skin models (human), Pre-clinical testing, Drug delivery pre-formulation, Innovative formulations, Oral bioavailability	Managing Dir.-CEO: Pachot (Jean) [founder, born 1960, Eng. biochemistry, ex-Roussel Uclaf, Aventis]
		(near Paris)	Mission: to conduct preclinical studies (in vitro ADME, Animal PK on rodents, Phys-Chem testing, Bioanalysis) for third parties, plus to develop own research in cell culture and innovative formulations, financed by CRO cash-flow	Sc.Dir.-CSO: Pachot (Jean)
			Clients: Pharmaceutical industry, Research labs, Cosmetic industry, Food industry, Veterinary industry	Chem.Dir.-CTO: Dini (Christophe) [born 1962, ex-Roussel Uclaf, Aventis]
www.oroxcell.com			Age: 16 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): privately owned (registered capital 2007 = 0.3 M€)
Oxincell	2006	Méditerranée	Contract, Services	Personal venture |	Virus	Preclin
		Montpellier	Key words: Mitochondria, Oxymetry measurement, Toxicology, Antivirals	Managing Dir.-CEO: Peyreigne (Christelle) [co-founder, born 1969, Ph.D. physiology, Inserm]
			Mission: to provide third parties with optimized oximetric analysis of mitochondrial activity	Sc.Dir.-CSO:
			Clients: Pharmaceutical industry, Biotechs, Research labs	Fin.Dir.-CFO:
www.oxincell.com			Age: 14 year(s)	BusDev:
				Financers (Hist.): privately owned
				Communication: no website news update since 2006 in February 2010
Palumed	2000	Midi-Pyrénées	Discovery, Drugs	Personal venture |	Infections	Preclin
		Toulouse	Key words: Anti-malarial, Antibacterial, Covalent bi-therapy, Trioxaquines	Managing Dir.-CEO: Meunier (Bernard) [born 1947, ex-Polytechnique (Professor), CNRS (President)]
			Mission: to develop new antimalarial agents and also new antibacterial molecules and chelating agents for the treatment of neurodegenerative diseases	Sc.Dir.-CSO:
			Clients: Pharmaceutical industry (Sanofi-Aventis)	Fin.Dir.-CFO:
www.palumed.com			Age: 20 year(s)	BusDev: Meunier-Chesny (Claudine) [born 1949]
				Financers (Hist.): IRDI, SOCRI, FCJE (CDC), GSO Capital, Viveris
PharmaLeads	2000	IDF	Design, Drugs	Personal venture |	Multiple	Trade
		Paris	(also, Discovery, Drugs)	Managing Dir.-CEO: Bourbié (Thierry) [born 1952, Polytechnique-Mines, Ph.D. Geophysics, ex-Suez, Schlumberger]
			Key words: Enzymes, Zinc Metallopeptidases, Substrates, Inhibitors, Fluofast, Analgesia	Sc.Dir.-CSO: Roques (Bernard Pierre) [Ph.D., ex-Inserm, Polytechnique (Assistant Prof.)]
			Mission: to develop custom design of substrates and inhibitors of all types of proteases for three main applications, on-demand design of optimised substrates and/or inhibitors for pharmaceutical companies, internal drug discovery in the field of analgesia, leading services in botulinum toxin detection and assay	Fin.Dir.-CFO: Maillard (Pierre) [MBA-ESSEC, ex-Dassault Aviation, Suez Environment]
www.pharmaleads.com			Clients: Research labs, Pharmaceutical industry	BusDev: Wurm (Michel) [M.D.]
			Age: 20 year(s)	Financers (Hist.): undisclosed
Pharnext	2007	IDF	Delivery, Drugs	Start-up |	Orphan	Clinical
		Paris	Key words: Drug Repositioning, Charcot Marie Tooth disease, Orphan drugs, Pleotherapy	Managing Dir.-CEO: Cohen (Daniel) [co-founder, born 1951, Ph.D., ex-Genset, Millenium]
			Mission: to develop innovative treatments for serious neurological diseases, notably peripheral neuropathies (Charcot Marie Tooth, peripheral diabetic neuropathy), and possibly Alzheimer, by implementing a drug repositioning approach which aims to expand the indications for existing medicines	Sc.Dir.-CSO: Chumakov (Ilya) [Ph.D. chemistry, D.Sc. Molecular Biology, ex-CEPH, Genset, Serono Genetics Institute
			Clients: Prescribers	Fin.Dir.-CFO: Heidsieck (Loïc) [ex-Arthur Young, Autologic, Franklin Mint, Serono, Genset]
www.pharnext.com			Age: 13 year(s)	BusDev:
				Financers (Hist.): Truffle Capital, Aurinvest, Financière Boscary, Parinvest (Jean-Charles Naouri), Financière Gaspard
PhenoPro	2007	Alsace	Contract, Services	Spin-off |	Studies	Trade
		Illkirch	(also, Contract, Research)	Managing Dir.-CEO: Schaeffer (Catherine) [born 1962]
		(near Strasbourg)	Key words: Translational medicine, Mouse phenotyping, Targets	Sc.Dir.-CSO:
			Mission: to provide third parties with advanced mouse phenotyping-based translational medicine tools and expertise, in order to improve biopharmaceutical drug R&D productivity and patient access to safer and more efficacious drugs	Fin.Dir.-CFO:
www.phenopro.com			Clients: Research labs	BusDev: Bocquel (François) [M.D., I.A.E., ex-Erudia, UCB Pharma, Parke Davis, Pfizer
			Age: 13 year(s)	Financers (Hist.): privately owned
				Communication: no legal accounting information available since inception
Pherecydes Pharma	2006	IDF	Discovery, Drugs	Spin-off |	Infections	Preclin
		Romainville	Key words: Antibacterials, Phage genes, Emerging problems, Defense, Bio-threat, Libraries of bacteriophages	Managing Dir.-CEO: Gabard (Jérôme) [born 1961, Ph.D., ex-Marketech, DuPont de Nemours]
		(near Paris)	Mission: to develop, then to introduce new products against multi-resistance bacteria, combining surveillance, detection and therapeutic tools based on phage technology, as a bio-defense and bio-security company	Sc.Dir.-CSO: Iris (François) [co-founder]
			Clients: undisclosed	R&D Dir.-CTO: Pouillot (Flavie) [Ph.D. Microbiology, ex-Institut Pasteur]
www.pherecydes-pharma.com			Age: 14 year(s)	BusDev:
				Financers (Hist.): Biosecurity, Financière de Brienne
PolyIntell	2004	IDF-Normandy	Contract, Research	Personal venture |	Studies	Subcontractor
		Val-de-Reuil (south Rouen)	(also, Contract, Manufacture)	Managing Dir.-CEO: Naraghi (Kaynoush) [co-founder, born 1970, Ph.D., Ms. management]
			Key words: Molecularly Imprinted Polymers, MIP, AFFINIMIP, Intelligent polymers, Selectivity, Solid phase extraction, Purification, Miniaturisation, Hydrogel, Sample preparation, Diagnostics	Sc.Dir.-CSO: Bayoudh (Sami) [co-founder, Ph.D.]
			Mission: to develop, manufacture and market more accurate analytical and diagnostic tools for pharmaceutical R&D and food safety, plus to operate own research in new polymers, financed by CRO cash-flow	Oper.Dir.-COO: Arotçarena (Michel) [Ph.D.]
www.polyintell.com			Clients: Pharmaceutical industry, Chemical industry, Food industry	Fin.Dir.-CFO:
			Age: 16 year(s)	BusDev:
				Financers (Hist.): privately owned
Proteogenix	2003	Alsace	Discovery, Diagnostics	Personal venture |	Cancers	Trade
		Oberhausbergen	(also Contract, Services)	Managing Dir.-CEO: Funfrock (Philippe) [co-founder, born 1978]
		(near Strasbourg)	Key words: Custom Antibodies, Recombinant proteins, Peptide synthesis, Gene synthesis, Cancer screening, Biomarkers	Sc.Dir.-CSO: Hopfner (Raphaël)
			Mission: to discover new diagnostic markers in cancer through targeted screenings and to provide third parties with polyclonal and monoclonal antibody development, recombinant protein production and purification, gene synthesis and peptide synthesis	Fin.Dir.-CFO:
www.proteogenix-antibody.com			Clients: Research labs	BusDev:
			Age: 18 year(s)	Financers (Hist.): Oséo, privately owned
				Note : Proteogenix will move in brand new state of the art facilities by 2011
Protexel	2000	IDF	Discovery, Drugs	Spin-off |	Liver	Clinical
		Paris	Key words: Immunology, Alcoholic hepatitis, Liver cancer, Cirrhosis, Chemical mimetics, Anti-oxydant, Superoxyde dismutase, Mangafodipir	Managing Dir.-CEO: Batteux (Frédéric) [Batteux (Arman), born 1939, legally as President]
			Mission: to develop innovative treatments for severe liver conditions	Sc.Dir.-CSO:
			Clients: Pharmaceutical industry (own development up to phase III)	Fin.Dir.-CFO:
www.no-website.net			Age: 20 year(s)	BusDev:
				Financers (Hist.):
				Note : no Company website since inception
PX’Therapeutics	2000	Rhône-Alpes	Contract; Research	Personal venture |	Multiple	Trade
		Grenoble	(also, Contract, Manufacturing)	Managing Dir.-CEO: Rousselle (Tristan) [co-founder, born 1970, Ph.D. cellular biology]
			Key words: Recombinant protein engineering	Sc.Dir.-CSO: Mouz (Nicolas) [co-founder, born 1966, Ph.D. molecular biology]
			Mission: to develop biotherapeutics (valuable recombinant proteins) from early stage research up to cGMP production through its specialized technology and manufacturing platforms Protein’eXpert, PX’Monoclonals and PX’Pharma, for third parties	Prod.Dir.-CTO: Mouz (Sebastien) [Ph.D.]
www.px-therapeutics.com			Clients: Pharmaceutical industry, Biotechs	Fin.Dir.-CFO:
			Age: 20 year(s)	BusDev: Untereiner (Claire)
				Financers (Hist.): Vizille Capita (and others), privately owned (registered capital 2007= 0.13 M€)
Quantum Genomics	2006	IDF	Discovery, Drugs	Start-up |	Multiple	Preclin
		Massy	Key words: Academic, Development platform, Co-partnering R&D	Managing Dir.-CEO: Segard (Lionel) [born 1968, Biochemistry, ex-Inserm-Transfert (CEO), IBM, TFSM]
		(near Paris / HQ	Mission: to maximize the developments and discoveries of academic research into breakthrough treatments for human disease, in cardiovascular diseases, neurology and metabolic related diseases	Sc.Dir.-CSO: Riffaud (Jean-Pierre) [Pharm.D., ex-Cellpep, NicOx, Fournier, Debat]
		Jersey City	Clients: Pharmaceutical industry	Fin.Dir.-CFO:
www.quantum-genomics.com		USA)	Age: 15 year(s)	BusDev:
				Financers (Hist.):
Rhenovia Pharma	2007	Alsace	Contract, Research	Personal venture |	CNS	Proof-of-Concept
		Mulhouse	Key words: Alzheimer, Biosimulation, Computational neuroscience, Memory	Managing Dir.-CEO: Bischoff (Serge) [co-founder, born 1948, Ph.D. neuropharmacology, ex-Novartis]
			Mission: to contribute to discover new medicines against Alzheimer’s and other central nervous system (CNS) diseases, by developing breakthrough biosimulation platforms for memory and other CNS functions	Sc.Dir.-CSO: Baudry (Michel) [co-founder, born 1948, Eng. Ecole Polytechnique, Prof. engineering (Los Angeles), Ph.D.]
			Clients: Pharmaceutical industry, Biotechs	Oper.Dir.-COO: Faupel (Michel) [co-founder, ex-Novartis]
www.rhenovia.com			Age: 13 year(s)	Fin.Dir.-CFO:
				BusDev: George (Florian) [Ph.D. chemistry]
				Financers (Hist.): privately owned, no outisde investors (registered capital 2007 = 0.126 M€)
ScarCell Therapeutics	2007	IDF	Design, Drugs	Spin-off |	Cardiovasc	Proof-of-Concept
		Paris	Key words: Cell therapy project, Transplantation, Cardiovascular	Managing Dir.-CEO: Augier (Jean-Jacques) [legally as President, born 1953]
			Mission: to carry out an autologous gingival fibroblasts transplantation in order to repair injured tissues, in particular in the field of cardiovascular pathology (vascular prosthesis for abdominal aortic aneurysm, atherosclerosis,…) and others	Sc.Dir.-CSO:
			Clients: undisclosed	Fin.Dir.-CFO:
www.scarcell-therapeutics.com			Age: 13 year(s)	BusDev:
				Financers (Hist.):
				Note : URL not renewed in time (October 2009), still unavailable (February, May, October 2010, April 2011, December 2012), but legally company still active (with a new President since July 2012, Laurent Cezard, born March 1969
Sisène Biotechnologies	2007	IDF	Discovery, Drugs	Academic |	Cancers	Preclin
		Paris	Key words: Cancer, Vegf, Anti-angiogenics, Ophtalmology	Managing Dir.-CEO: Marsac (Jean) [born 1943, co-founder, M.D., Professor]
			Mission: to discover and develop new anti-angiogenic biotherapies, in cancers and ophtalmology	Sc.Dir.-CSO: Plouët (Jean) [deceased, co-founder, M.D., Ph.D., Professor, Inserm, ex-Abtech, Gencell, AP-HP Lariboisière]
			Clients: Pharmaceutical industry (own development up to clinical trials)	Oper.Dir.-COO: Garreau (Martine) [born 1951, M.D., ex-Synthelabo]
www.no-website.net			Age: 13 year(s)	Fin.Dir.-CFO:
				BusDev:
				Financers (Hist.): ARC, ANR, InCA
				Note (November 2011) : the new company website is available
Skuld-Tech	1999	Méditerranée	Design, Diagnostics	Spin-off |	Multiple	Preclin
		Montpellier	(also, contract, research)	Managing Dir.-CEO: Ritter (Didier) [co-founder, born 1969, Ms. molecular biology, MBA, ex-Bio2R (founder)]
			Key words: Biomarkers, Genomics, Pharmaco-genomics, Bio-informatics, Biosensors, SAGE	Sc.Dir.-CSO: Piquemal (David) [co-founder, Ph.D., Prof. genomics]
			Mission: to select and validate biomarkers, bioinformatics, biosensors, leading to design new diagnosis, identify new targets, and generate new leads for biopharmaceutical companies and personalized medicine	Fin.Dir.-CFO: Outrebon (Philippe) [co-founder, Ms. sciences, ex-Ernst & Young]
www.skuldtech.com			Clients: Research labs	BusDev: Outrebon (Philippe)
			Age: 21 year(s)	Financers (Hist.): Oseo, Regional Territory Body, Private Investors
Stentys	2006	IDF	Design, Devices	Start-up |	Cardiovasc	Trade
		Paris	Key words: Stent, Heart-Attack, Revascularisation,	Managing Dir.-CEO: Issenmann (Gonzague) [co-founder, born 1972, MBA, ex-CordisJ&J]
			Mission: to develop a new generation of self-expanding stents or self-apposing stents, specialized in the treatment of heart attacks (or Acute Myocardial Infarction)	Sc.Dir.-CSO:
			Clients: Device Industry, Hospitals	Med.Dir.: Spaargaren (René) [M.D., Medtronic, Boston Scientific, EV3]
www.stentys.com			Age: 14 year(s)	Mktg&Sales: Goffart (Lucien) [MBA, ex-J&J, Abbott , Volcano]
				Fin.Dir.-CFO: Piot (Stanislas) [Ms. finance and economics, ex-Ipsogen, Banque Worms, Crédit Lyonnais, Oddo, Natixis]
				BusDev:
				Financers (Hist.): Sofinnova Partners, Scottish Equity Partners, Crédit Agricole Private Equity, FSI, Public (registered capital 2009 = 0.16 M€)
Synapcell	2005	Rhône-Alpes	Contract, Research	Personal venture |	CNS	Subcontractor
		Grenoble	Key words: Preclinical development, CNS, Epilepsy, Neuronal networks	Managing Dir.-CEO: Roucard (Corinne) [born 1969, co-founder, Ph.D., ex-Synapcell (Project Leader)]
			Mission: to provide third parties with customized solutions for preclinical evaluation of CNS therapeutics and with consulting, pre-designed and customized programs to expertise drug candidates of the biopharmaceutical industry, and also to develop own research innovative tools	Sc.Dir.-CSO: Bressand (Karine) [born 1971, Ph.D.]
			Clients: Research labs	Fin.Dir.-CFO: Roche (Yann) [born 1974, Ph.D. biology, Ms. Management]
www.synapcell.com			Age: 15 year(s)	BusDev: Roche (Yann)
				Financers (Hist.): privately owned (registered capital 2006 = 0.09 M€)
Synprosis	2003	Méditerranée	Discovery, Immunology	Personal venture |	Vaccines	Preclin
		Fuveau	(also Contract, Manufacturing)	Managing Dir.-CEO: Salles (Jean-Pierre) [born 1954, Pharm.D., ex-Laphal (Dir. R&D)]
		(near Marseille)	Key words: HIV1 vaccine, Synthetic peptides	Sc.Dir.-CSO:
			Mission: to provide custom peptide synthesis (notably vaccines) in solid phase manufacture with high quality for basic research and for therapeutic applications (cGMP) and to develop own immunological compounds	Fin.Dir.-CFO:
www.synprosis.com			Clients: Pharmaceutical industry	BusDev: Pomarède (Richard)
			Age: 17 year(s)	Financers (Hist.): privately owned (registered capital 2007 = 0.23 M€)
Tc Land Expression	2002	Bretagne	Design, Diagnostics	Spin-off |	Multiple	Preclin
		Nantes	Key words: Biomarkers, Transplantation, Auto-immune diseases	Managing Dir.-CEO: Tchelingerian (John) [born 1965, Ph.D. neuroscience, ex-Neurotech (co-founder), Key Obs (co-founder), Diatos (CEO)]
			Mission: to develop gene expression biomarkers in transplantation and immunology through proprietary strategy of personalized medicine	Sc.Dir.-CSO: Guillet (Marina) [born 1973, Ph.D., ex-TcLand (CEO)]
			Clients: Pharmaceutical industry, Research labs	Clin.Dir.-CMO: Larcier (Patrick) [Pharm.D., MBA Essec, ex-Neovacs, Biogen-Idec, Quintiles, Parexel, GSK]
www.tcland-expression.com			Age: 18 year(s)	Fin.Dir.-CFO: Jaffré (Philippe) [MBA, ex-Novartis, Chiron, Dana Capital]
				SalesMktg: Kazek (Elodie) [Pharm.D., ESSEC, ex-BioMerieux, Fresenius Kabi, Merck KgAa]
				BusDev: Payne (Peter) [Ms. pharmacology, ex-Quintiles, Wellcome, Sterling Drug, Glaxo], also Head of US-Business
				Financers (Hist.): Auriga Partners, Debiopharm, Genzyme Ventures, Quest For Growth, Beviguen
				Note: the previous URL, tcland-biotech.com, has been replaced by tcland-expression.com, late 2010
Theraclion	2004	IDF	Development, Devices	Start-up |	Multiple	Clinical
		Paris	Key words: Ultrasound, Parathyroidism, Prostate cancer, Fibroadenoma, UNIS	Managing Dir.-CEO: Burel (Jean-Yves) [born 1951, ex-GE Healthcare]
			Mission: to develop non-invasive solutions, based on High Intensity Focussed Ultrasound (HiFu), for the non-invasive ablation of small tumors and the treatment of secondary hyperparathyroidism, thyroid nodules	Sc.Dir.-CSO: Lacoste (François) [co-founder, born 1950, Eng. physics, ex-Technomed, Cilas-Alacatel, Perkin Elmer]
			Clients: undisclosed	R&D Dir.-CMO: Yon (Sylvain) [born 1974, ESCPI, Ph.D. physics, ex-Echosens (co-founder)]
www.theraclion.fr			Age: 16 year(s)	Fin.Dir.-CFO:
				BusDev: Del Bourgo (David) [Eng. UIT Compiègne, MBA Chicago, ex-Orbotech, Advention Business Partners, General Electric Healthcare]
				Financers (Hist.): Truffle Ventures
Theradiag	1987	IDF	Discovery, Diagnostics	Start-up |	Allergy	Trade
		Marne-la-Vallée	(also, Design, Devices)	Managing Dir.-CEO: Finance (Michel) [Ms. EM Lyon, ex-Neovacs, Carmat, Flamel Technologies, Aventis]
		(near Paris)	Key words: Auto-immune diseases, Allergy test monitor, Caris, Fidis, Luminex	Tech.Dir.-CTO: Parussini (Ermis), Ms.Sc. molecular biology, ex-Biomérieux
			Mission: to develop, manufacture and market quality and innovative IVD products for the diagnostic market of auto-immune diseases, allergies and infectious diseases	Sc.Dir.-CSO:
www.theradiag.com			Clients: Pharmaceutical industry	Sales Dir.: Sallen (Eric), Abbott, Becton Dickinson, Saint Gobain, Kottermann, Seroa]
			Age: 33 year(s)	Admin.Dir.: François (Fabienne) [MBA, HR experience]
				BusDev:
				Financers (Hist.): Truffle Venture (majority share), CDC Entreprise, AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova
				Communication:with company name change, the URL moves and www.bmd-net.com is deleted (June 2012)
Theralpha	2009	Méditerranée	Discovery, Drugs	Spin-off |	Pain	Preclin
		Sophia Antipolis	Key words: Pain, Acid-Sensing-Ion-Channel (ASIC), Sublingual	Managing Dir.-CEO: Dellamonica (David) [ESG, MBA, ex-TxCell, Nex&Com, Polygram Universal, Ogilvy Healthcare]
		(near Nice)	Mission: to develop innovative peptide-based drugs for the treatment pain	Sc.Dir.-CSO: Lazdunski (Michel) [Ph.D., Professor, CNRS]
			Clients: Pharmaceutical industry (own development up to clinical trials)	Fin.Dir.-CFO:
www.theralpha.com			Age: 11 year(s)	BusDev:
				Financers (Hist.): privately owned (registered capital 2009 = 0.04 M€)
TheraVectys	2005	IDF	Discovery, Immunology	Spin-off |	Vaccines	Preclin
		Paris	Key words: Vaccines, DNA Flap Lentivirus, Veterinary	Managing Dir.-CEO: Gohaud (Romain) [born 1949]
			Mission: to develop new vaccines derived from the DNA Flap Lentivirus technology	Sc.Dir.-CSO: Charneau (Pierre) [Ph.D. virology, Institut Pasteur]
			Clients: Pharmaceutical industry (own development up to clinical trials)	Fin.Dir.-CFO:
www.theravectys.com			Age: 15 year(s)	BusDev:
				Financers (Hist.): privately owned (registered capital 2006 = 0.06 M€)
Transgene	1979	Alsace	Discovery, Immunology	Start-up |	Vaccines	Clinical
		Strasbourg	Key words: Therapeutic vaccines, Immuno-therapy, Cancer, Infectious diseases	Managing Dir.-CEO: Archinard (Philippe) [born 1959, Ph.D. Biochemistry, Eng. Chemistry, ex-Innogenetics (CEO), Biomérieux]
			Mission: to discover and develop gene-based therapeutic vaccines and immunotherapy products	Sc.Dir.-CSO: Bonnefoy (Jean-Yves) [Ph.D. immunology, ex-Pierre Fabre, Glaxo Wellcome]
			Clients: Prescribers	Med.Dir.-CMO: Adda (Nathalie) [M.D., ex-Vertex]
www.transgene.fr/us			Age: 42 year(s)	Fin.Dir.-CFO: Boissel (Stéphane) [MBA (Chicago), ex-PWC, Innate Pharma, Lazard]
				BusDev:
				Financers (Hist.): Mérieux (53%), Institutional investors, AFM, Public
Trophos	1999	Méditerranée	Discovery, Drugs	Personal venture |	Multiple	Clinical
		Marseille	Key words: Embryonic neurones, Parkinson’s diseases, Huntington’s diseases, Cardiac ischemia, IRIstop	Managing Dir.-CEO: Placet (Christine) [Sup de Co (Marseille), ex-Ernst & Young]
			Mission: to develop drugs to prevent neuronal loss in patients with neurodegenerative diseases, based on proprietary screening system employing sick neurons (focused in 2009, onto neuroprotection and cardioprotection)	Sc.Dir.-CSO: Pruss (Rebecca) [Ph.D., ex-Sanofi-Synthélabo]
			Clients: Prescribers	Med.Dir.-CMO: Abitbol (Jean-Louis) [M.D., ex-Parke Davis, Pfizer, Pierre Fabre]
www.trophos.com			Age: 22 year(s)	Fin.Dir.-CFO:
				BusDev: Harris (Stephen) [Ph.D., ex-GSK]
				Financers (Hist.): Société Générale Assets Management (SGAM), Turenne Capital Partners, Viveris Management, SOFIPACA, SOFIMAC OTC Asset Management, CM-CIC Asset Management, Blue Medical, AFM (French Muscular Dystrophy Association), Innoveris, business angels
TxCell	2001	Méditerranée	Discovery, Immunology	Spin-off |	Inflammation	Clinical
		Sophia Antipolis	Key words: Cell Therapy, Inflammatory, Autoimmune diseases	Managing Dir.-CEO: Meyer (François) [born 1948, Ph.D. molecular biology, ex-Ciba-Geigy, Sandoz, Rhone Poulenc Rorer, Aventis]
		(near Nice)	Mission: to develop new therapies to cure inflammatory and autoimmune diseases, such as Crohn’s disease, multiple sclerosis, psoriasis or rheumatoid arthritis, by bringing regulatory T cells to the body	Sc.Dir.-CSO: Foussat (Arnaud) [Ph.D., ex-Inserm]
			Clients: Prescribers	Med.Dir.-CMO: Forte (Miguel) [M.D., Ph.D., ex-B.M.S., Nabi Pharmaceuticals, UCB]
www.txcell.com			Age: 19 year(s)	Fin.Dir.-CFO: Sarlot (Christophe)
				BusDev:
				Financers (Hist.): Auriga Partners, AXA Private Equity, BioAm, CDC, SPEF Venture, Inserm-Transfert
UROsphere	2004	Midi-Pyrénées	Contract, Research	Spin-off |	Multiple	Preclin
		Labège	Key words: Urinary incontinence, Benign prostatic hyperplasia (BPH), Sexual dysfunctions, Renal disorders	Managing Dir.-CEO: Lluel (Philippe) [born 1966, Ph.D. pharmacology]
		(near Toulouse)	Mission: to provide third parties with research preclinical services for urology and renal pathologies	Sc.Dir.-CSO: Palea (Stefano) [born 1962, Ph.D. pharmaceutical chemistry, ex-Sanofi-Aventis, Glaxo-Wellcome]
			Clients: Pharmaceutical industry	Fin.Dir.-CFO:
www.urosphere.com			Age: 16 year(s)	BusDev:
				HR.Dir: Mignotte-Darmon (Brigitte) [DESS Management]
				Financers (Hist.): privately owned (registered capital 2006 = 0.13 M€)
				note (March 2010) : new website unveiled
Vaxon Biotech	2004	IDF	Discovery, Immunology	Personal venture |	Vaccines	Clinical
		Paris	Key words: Therapeutic vaccines, Cryptic peptides	Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)]
			Mission: to develop innovative therapeutic vaccines for the treatment of cancer including lung, prostate, breast, renal, liver and colorectal cancer, using proprietary technology of optimized cryptic peptides	Sc.Dir.-CSO: Kosmatopoulos (Kostas) [born 1950, M.D., Ph.D., also Chairman, ex-Inserm]
			Clients: Prescribers	Fin.Dir.-CFO:
www.vaxon-biotech.com			Age: 17 year(s)	BusDev:
				Financers (Hist.): Génopole 1er Jour (G1J), Inserm-Transfert, privately owned
Vectalys	2005	Midi-Pyrénées	Design, Drugs	Personal venture |	Virus	Preclin
		Labège	(also, Contract, Resarch)	Managing Dir.-CEO: Bouillé (Pascale) [born 1967, founder, Ph.D. molecular biology, secretary JEInnov]
		(near Toulouse)	Key words: Gene sequences, Gene transfer, Viral vector, Retrovirus, Lentivirus	Sc.Dir.-CSO:
			Mission: to provide third parties with a platform of retroviral (RV), lentiviral (LV) and adeno-associated virus (AAV) based vectors that efficiently introduce human gene sequences into a wide variety of human cells to knock-in or knock-down specific proteins	Fin.Dir.-CFO:
www.vectalys.com			Clients: Pharmaceutical industry	BusDev:
			Age: 15 year(s)	Financers (Hist.): pricately owned (registered capital 2006 = 0.05 M€)
Vivalis	1999	Bretagne	Design, Manufacture	Start-up |	Multiple	Preclin
		Nantes	(also, Discovery, Immunology)	Managing Dir.-CEO: Grimaud (Franck) [co-founder, born 1966, MBA]
			Key words: Vaccines, Flu, Viral diseases, EBx Cell line, Therapeutic protein, Cell Culture, EB66	Sc.Dir.-CSO: Mehtali (Majid) [Ph.D., ex-Deltagen, Transgene, Rhône Mérieux]
			Mission: to provide innovative cell-based solutions for the industrial manufacture of viral vaccines and therapeutic proteins, and to develop own vaccines and drugs in order to prevent and treat viral diseases (also deeply involved in veterinarian vaccines)	Fin.Dir.-CFO: Rousseau (Philippe) [HEC, ex-Exonhit, Valigen, Genset, Mars, Paribas]
www.vivalis.com			Clients: Pharmaceutical industry (own development up to clinical trials)	BusDev: Miniou (Pierre) [Ph.D., ex-Pierre Fabre, Transgene]
			Age: 21 year(s)	Financers (Hist.): Grimaud-La Corbière Group, Public
				Note : company legal domiciliation : Roussay (49)
XenTech	2006	IDF	Contract, Research	Spin-off |	Cancers	Preclin
		Évry	(also, Discovery, Diagnostics)	Managing Dir.-CEO: Coulomb (Bertrand) [born 1955, Pharm.D., ex-Nycomed, Altana Pharma, Pasteur-Sanofi Diagnostics, UPSA (BMS), Servier]
		(near Paris)	Key words: Theranostics, Preclinical oncology, Tumor models	Sc.Dir.-CSO: Judde (Jean-Gabriel) [co-founder, born 1954, Ph.D., ex-MD Anderson Cancer Center, NCI, Institut Curie, also board chairman]
			Mission: to provide specialized services in predictive preclinical oncology, to develop own treatment diagnostics derived from patient-derived tumor xenografts	Oper.Dir.-COO: Leuraud (Pascal) [co-founder, Ph.D.]
www.xentech.eu			Clients: Pharmaceutical industry, Biotechs, Research labs	Fin.Dir.-CFO:
			Age: 14 year(s)	BusDev: Bazzacco (Paola)
				Financers (Hist.): privately owned (registered capital 2007 = 0.05 M€), Aurinvest Capital 2